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Summary 
Mammals have 7 Sirtuin isoforms (SIRT1–7) localized in different subcellular compartments 
and with different functions. Sirt6 is a heterochromatin-associated protein that serves in the 
regulation of telomere maintenance, DNA repair and gene expression. A Sirt6 knockout 
causes aging-associated degeneration in mice. Conversely, Sirt6 overexpression has been 
reported to extend lifespan in male mice. Thus, activators of Sirt6 are considered to be 
attractive therapeutics to treat cancer and age-related diseases. Sirtuin-activating compounds 
(STACs) were initially described to activate Sirt1, and bind to the Sirt1’s unique N-terminal 
segment (SBD domain). In contrast, progress towards the development of activators which 
modulate the activity of other Sirtuin isoforms that lack the Sirt1’s SBD domain has been 
significantly taken up speed only recently.  
The pyrrolo[1,2-a]quinoxaline-derived compound UBCS038 were previously characterized as 
a very weak Sirt6 activator. We screened a panel of pyrrolo[1,2-a]quinoxaline-derived 
derivatives and identified several compounds as more potent activators for Sirt6-dependent 
deacetylation of peptide substrates, histone proteins and complete nucleosomes. Furthermore, 
these compounds showed no effect on Sirt1, 2 and 3, but promoted the desuccinylase activity 
of Sirt5. Solving the complex structures by using X ray crystallography revealed that these 
compounds as the first synthetic Sirt6 activators bind to the Sirt6 specific acyl channel 
branching from the catalytic core and activate Sirt6 deacetylation by an allosteric mechanism, 
which can explain their different effects against acyl substrates. Moreover, structure-activity 
relationship analyses indicate that the presence of a nitrogen atom in the meta position of the 
pyridine group is crucial for ligand affinity or Sirt6 activation. Our data reveal promising 
acyl-selective Sirt6 activators and offer clues for the development of Sirt6 drug-like 
compounds as molecular tools and potential therapeutics.  
Next, we utilized a robust mass spectrometry-based assay to determine the effect of quercetin 
on Sirtuins. We confirmed the weak activation effect of quercetin for Sirt6 and found out that 
quercetin can inhibit other Sirtuin isoforms. We solved crystal structures of a Sirt6/quercetin 
complex and a Sirt2/quercetin complex to reveal two mutually exclusive binding modes that 
lead to the dual effects of quercetion among Sirtuins. Based on the structural information, we 
have identified a novel quercetin derivative, namely isoquercetin, able to activate Sirt6 with 
improved selectivity. We then determined the crystal structure of Sirt6 and isoquercetin to 
better understand its activation mechanism. Moreover, we also confirmed the effects of 
quercetin derivatives catechin gallate (the first potent Sirt6 inhibitor) and cyaniding (the most 
robust Sirt6 activator) in our mass spectrometry assay and further determined the crystal 
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structures of Sirt6 in complex with these two compounds. Our results demonstrate that the 
substitution in the C ring of quercetin can significantly alter the effect of compounds from 
activation to inhibition, and reveal molecular features essential for further drug development. 
Trichostatin A (TSA) inhibits classical HDACs by chelating the zinc ion in the active site, but 
in Sirtuins the zinc ion does not play a catalytic role and its binding site is remote from the 
catalytic site. Surprisingly, TSA is also identified to show promising efficacy towards Sirt6, 
while demonstrates no appreciable inhibitory effect on Sirt1-3 or Sirt5.We obtained the 
Sirt6/TSA complex structure by soaking experiment. We found that TSA binds into the C 
pocket of the NAD+ binding site and inserts into Sirt6's specific acyl binding channel, which 
thus explains its relative specificity for Sirtuin isoforms. Binding studies further revealed that 
TSA binds to Sirt6 in a noncompetitive manner with respect to ADP-ribose (fragment of 
NAD+) or substrate, suggesting that TSA might acts as sirtuin inhibitor via binding to the C 
pocket upon the dissociation of NAM group and prevent product release by stabilizing the 
intermediate complex. Our data provides insight into the TSA binding site and the inhibition 
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Zusammenfassung 
In Säugetieren existieren 7 Sirtuin Isoformen (SIRT1-7), die in verschiedenen Zellkompartimenten 
lokalisiert sind und verschiedene Funktionen ausüben. Sirt6 ist ein mit Heterochromatin assoziiertes 
Protein, welches in der Regulation der Erhaltung von Telomer-Strukturen, DNA-Reparatur, und 
Genexpression  involviert ist. Ein Sirt6 Knockout in Mäusen führt zu beschleunigtem, altersbedingtem 
Verfall.  Im Gegensatz dazu führt die Überexpression von Sirt6 zur Verlängerung der Lebensspanne 
männlicher Mäuse. Daher werden Sirt6-Aktivatoren als attraktive potentielle Therapeutika für Krebs 
und alterungsbedingte Krankheiten angesehen. Synthetische Sirtuin-Aktivatoren (Sirtui -activati g 
co pou ds, STACs) wurden ursprünglich für Sirt1 beschrieben und binden an eine Sirt1-spezifische 
Domäne N-terminal von der katalytischen Domäne (SBD, für STAC-binding domain). Die 
Entwicklung von Aktivatoren anderer Sirtuin-Isoformen, welche die einzigartige Sirt1 SBD nicht 
besitzen, hat sich erst kürzlich beschleunigt.   
Die von Pyrrolo[1,2-a]Chinoxalin abgeleitete Substanz UBCS038 ist als schwacher Sirt6-Aktivator 
beschrieben worden. Im Zuge dieser Arbeit wurden verschiedene Pyrrolo[1,2-a]Chinoxalin Derivate 
synthetisiert und es konnten verschiedene Substanzen, welche die Deacetylierungsaktivität von Sirt6 
gegenüber Peptid-Substraten, Histonproteinen und Nucleosomen stimulieren, identifiziert werden. 
Darüber hinaus zeigten diese Substanzen keinen Effekt auf Sirt1, 2, und 3, förderten jedoch die 
Desuccinylase-Aktivität von Sirt5. Strukturelle Studien zeigten, dass diese Substanzen – die ersten 
charakterisierten Sirt6-Aktivatoren – in dem Sirt6-spezifischen Acylkanal binden, der vom 
katalytischen Zentrum ausgeht und die Sirt6 Deacetylierung durch einen allosterischen Mechanismus 
aktiviert. Dies erklärt auch die verschiedenen Effekte auf Acylsubstrate. Weiterhin zeigen die 
Analysen der Struktur-Wirkungsbeziehung, dass die Präsenz eines Stickstoffatoms in meta-Stellung 
zum Pyridin-Rest essentiell für die hochaffine Bindung sowie Sirt6 Aktivierung ist. Unsere Daten 
weisen auf vielversprechende acylselektive Sirt6 Aktivatoren hin und liefern Hinweise zur 
Entwicklung von Wirkstoffkandidaten, die als molekulare Werkzeuge und potentielle Therapeutika 
dienen können.  
Des Weiteren verwendeten wir einen auf massenspektrometrischer Analyse beruhender Assay, um die 
Wirkung von Quercetin auf Sirtuine zu untersuchen. Wir konnten bestätigen, dass Quercetin Sirt6-
aktiviert, aber andere Sirtuinisoformen inhibiert. Unsere Kristallstrukturen von Sirt6 und Sirt2 im 
Komplex mit Quercetin zeigen, dass die Substanz in zwei nicht miteinander zu vereinbarenden 
Bindungsmodi an Sirt6 bzw. Sirt2 bindet und diese die unterschiedlichen Wirkungen von Quercetin 
auf verschiedene Sirtuinisoformen bedingen. Auf Basis dieser Kristallstrukturen haben wir ein 
Quercetin-Derivat, nämlich Isoquercetin, definiert, welches eine erhöhte Selektivität gegenüber Sirt6 
zeigt. Um den Mechanismus, der zur Aktivierung führt, zu verstehen, haben wir die Kristallstruktur 
des Sirt6/Isoquercetin-Komplexes gelöst. Außerdem bestätigten wir die Effekte der Quercetinderivate 
Catechin-Gallat (der erste potenter Inhibitor) und Cyanidin (der stärkste Sirt6-Aktivator) auf Sirt6 mit 
unserem Massenspektrometrieassay und lösten die Kristallstrukturen von Sirt6 in Komplex mit diesen 
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Verbindungen. Unsere Ergebnisse zeigen, dass der Austausch im C-Ring von Quercetin signifikant 
den Effekt der Substanz von Aktivierung zu Hemmung hin verändern kann und schaffen die 
molekulare Grundlage für die weitere Medikamentenentwicklung.  
Trichostatin A (TSA) inhibiert klassische HDACs, indem es das Zink-Ion im katalytischen Zentrum 
komplexieren. In Sirtuinen hingegen spielt das Zink-Ion keine katalytische Rolle und die 
Zinkbindestelle befindet sich nicht in der Nähe des katalytischen Zentrums. Überraschenderweise 
zeigt TSA dennoch eine vielversprechende Wirkung auf Sirt6, aber besitzt für Sirt1-3 bzw. Sirt5 
keinen inhibitorischen Effekt. Wir konnten die Komplexstruktur von Sirt6 mit TSA lösen und fanden 
heraus, dass TSA in der C-Tasche der NAD+-Bindestelle bindet und sich in den Sirt6 spezifischen 
Kanal einfügt. Dies erklärt die Isoformspezifität. Bindungsexperimente ergaben ferner, dass TSA in 
einer nichtkompetitiven Weise zu ADP-ribose (Fragment von NAD+) oder einem Substrat an Sirt6 
bindet. Dies legt nahe, dass die inhibitorische Wirkung von TSA durch Bindung in der C-Tasche nach 
Dissoziation der NAM-Gruppe erfolgt und durch die Stabilisierung des Intermediatkomplexes die 
Freisetzung des Produktes verhindert wird. Unsere Daten beleuchten die molekulare Struktur der 
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1 Introduction 
1.1 Aging is associated with metabolism 
Aging is characterized by a time-dependent loss of physiological integrity at the organismal 
level. There is a general perception that human life expectancy has increased and the effects 
of aging as measured by appearance have diminished compared to the 1960s1. These 
observations have led to the question what are the cellular and molecular mechanisms that 
help to slow down the effect of aging and how to define the cause of aging at the cellular 
level2. Early theories were derived from simple model organisms like yeast, worms, and flies3, 
4. Many genes that affect lifespan in model organisms have been identified and have been 
shown to extend both maximum and average lifespans in lower organisms. Research on 
mammals has also experienced unprecedented progress in the past few decades; many 
pathways governing the aging processes have been identified in aging, dysfunctional cells.  
This work eventually led to the definition of several candidate hallmarks of ageing, such as 
genomic instability5-8, telomere attrition9-12, epigenetic alterations13, loss of proteostasis14, 
deregulated nutrient sensing15-17, mitochondrial dysfunction18, cellular senescence19-21, stem 
cell exhaustion22, and altered intercellular communication (Figure 1)23, 24.  
 
Figure 1: Aging has been defined as the time dependent deterioration of physiological 
integrity and several primary causes of aging have been designated as its hallmarks (Figure 
taken from López-Otín et al., 201325 with permission of Cell Press). 
Metabolism has been associated with aging since 80 years ago. Calorie restriction (CR) 
without malnutrition has been shown to delay senescence and extend the lifespan in rats26. An 
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increasing number of studies has confirmed the beneficial effect of CR in different species27. 
CR does not increase lifespan in all model organism, but CR was shown to increase health 
span in a variety of organisms and to prevent the onset of age-related diseases15. Strikingly, 
recent research revealed that the CR-mediated lifespan extension can be regulated by 
Sirtuins28. There is ample scientific evidence supporting this discovery.  CR has been shown 
to increase the expression level of several members of Sirtuins and alter the NAD+:NADH 
ratio to activate Sirtuins29. A knockout of any Sirtuin gene in mice results in the absence of 
some of the normally observed phenotypes during a CR30 regime. Many substrates targeted by 
Sirtuins  play important roles in the anti-aging effects of CR31.  Sirtuin-activating compounds 
were identified to mimic CR effects in mice on a normal diet32-36. The link between Sirtuin 
and calorie restriction is of particular interest as it may offer a new view on the design of 
drugs to slow aging and extend human health span. 
 
Figure 2: Nutrient-responsive signalling pathways affect many physiological processes with 
important effects on health and longevity (Figure taken from Bonkowski et al., 201637 with 
permission of Nature publishing group). 
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1.2 Sirtuins in Biology 
1.2.1 Roles of Sirtuin in longevity 
Sir2 is an NAD+-dependent deacetylase, and the silent information regulator (SIR) proteins 
were found to regulate gene expression and increase the replicative lifespan of yeast cells 
almost 20 years ago38. It has been demonstrated that the formation of transcriptional silencing 
in yeast requires the NAD+ dependent deacetylase activity of SIR239. During SIR2-mediated 
gene silencing, SIR2 was identified to deacetylate histones to provide high-affinity binding 
sites for SIR3 and SIR4, which in turn enables assembly of additional SIR2 protein and 
facilitates the spreading of silencing complexes along the chromosome40, 41. SIR2-mediated 
lifespan extension in yeast can be affected by enzymatically inactive SIR2 mutants and the 
NAD+ concentration, whose level is strongly correlated with the cellular stress response and 
nutrient limitation42. These findings offer the intriguing possibility that SIR2 related proteins 
could act as metabolic sensors that respond to nutrient input and are affected by the 
NAD+/NADH ratio to alter diverse physiological processes with an impact on metabolism 
and aging. Sirtuins thereby act as a link between metabolic rate and aging. 
1.2.2 The mammalian Sirtuins 
The SIR2 homologs found in mammals are termed Sirtuins (derived from "SIR-2-ins"). There 
are seven Sirtuin isoforms in mammals, and they can be divided into four classes based on 
their phylogenetic relationship43, 44. Mammalian sirtuins (Sirt1-7) differ in their subcellular 
localization and in their substrate specificity (Figure 3)45. Similar to yeast SIR2, the 
mammalian Sirtuins SIRT1, SIRT6 and SIRT7 are predominately found in the nucleus but 
differ in their subnuclear distributions46-48. Sirt2 primarily localizes in the cytoplasm49, 50, 
Sirt3-5 are characterized as mitochondrial Sirtuins51. However, Sirt1 & Sirt2 can shuttle 
between cytoplasm and nucleus in response to physiological stimuli. Sirt1-3 are much more 
catalytically active deacetylases than Sirt4-7, but there is growing evidence that mammalian 
Sirtuins are able to remove other lysine acyl moieties.  For example, Sirt5, has been found to 
be a more efficient desuccinylase, demalonylase and deglutarylase than deacetylase52,53. 
Consistently, knocking out Sirt5 in mice leads to elevated levels of lysine malonylation, 
succinylation and glutarylation on diverse mitochondrial proteins54. Furthermore, Sirt6 was 
found to exhibit 300-fold better efficiency for the hydrolysis of long chain fatty acyl groups 
from protein lysines than that of deaceylation in vitro55. However, several studies revealed 
that Sirt6 primarily acts as histone deacetylase in vivo56, 57. In addition, both Sirt4 and Sirt6 
have been reported to possess low mono-ADP-ribosylation activity58-60, and recently Sirt4 has 
Introduction 
 - 9 - 
been identified to show specific activity against hydroxymethylglutarylation61. Little is known 
about the deacylation specificity of Sirt7. The growing list of substrate acyl group chemistries 
has led to Sirtuins being considered as protein deacylases rather than deacetylases. 
 
Figure 3: Mammals have 7 Sirtuin isoforms that localize in different subcellular 
compartments and regulate different cellular functions (Figure taken from Michan et al., 
200748 with permission of Portland Press). 
Of the seven mammalian Sirtuin isoforms, Sirt1 is the best characterized family member. Sirt1 
was first described to modulate chromatin structure through histone deacetylation. It has also 
been implicated in deacetylation of non-histone targets involved in cell survival, DNA repair, 
stress response, inflammation, apoptosis and energy metabolism62, 63. Sirt2 is shown to 
deacetylate α-tubulin to regulate microtubule dynamics49. Sirt3-5 target a large variety of 
metabolic enzymes to mediate energy production, metabolism, apoptosis and stress 
response64, 14.  
Sirt6 was demonstrated to associate with heterochromatin and regulate chromatin structure to 
promote proper chromatin function in numerous physiological processes, including telomere 
maintenance and DNA repair (Figure 4)56, 57. SIRT6 deficiency in mice and cells was reported 
to result in the most striking phenotype among the seven mammalian sirtuins65-67. SIRT6- 
knockout mice are born with a low birth weight and suffer from a severe age-related 
degenerative phenotype that includes metabolic defects, loss of subcutaneous fat, chronic 
inflammation, and lymphopenia. Overall, these physiological defects result in a severely 
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reduced lifespan of about one month59. Sirt6 knockout cells exhibit genomic instability and 
increased sensitivity to DNA-damaging agents (DDAs) such as ionizing radiation (IR) and 
ROS. These observations indicate that there is defect in DNA repair and suggest a hypothesis 
that Sirt6 is able to promote DNA repair59, 68. Together, these studies suggest that Sirt6 
deficiency affects multiple cellular phenotypes with an impact on organismal health and 
aging. The studies in vitro showed that Sirt6 favors to remove long chain fatty acyl groups 
from protein lysines over acetyl group, and Sirt6 can promote secretion of tumor necrosis 
factor-a (TNFa) through lysine demyristoylation55. However, in vivo studies revealed that 
Sirt6 function is majorly associated with its deacetylase activity of lysines 9 and 56 on histone 
H356, 57.  
 
Figure 4: Sirt6 associates with heterochromatin to regulate numerous cellular functions 
(Figure taken from Kugel et al., 201469 with permission of Cell Press). 
Sirt6 can regulate transcription silencing of target genes by deacetylating specific histone 
lysine residues in their promoter region67, 70-72.  There is ample evidence for this functionality. 
First, nuclear factor-kappaB (NF-kB) is a nuclear transcription factor that affects multiple 
biological processes in inflammation, proliferation and aging. NF-κB activation contributes to 
the development of aging-associated diseases; earlier studies indicate that Sirt6 functions to 
suppress the transcriptional activity of nuclear NF-kB by deacetylating histone H3 at position 
K9 in its promoter region to alter the expression of a subset of NF-kB target genes71. Second, 
Hypoxia Inducible Transcription factor 1a (Hif1a) is a transcription factor that mediates the 
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cellular adaptation to the nutritional environment and regulates the expression of glycolytic 
enzymes72, 73. SIRT6 was found to bind to Hif1a and deacetylate histone H3 at position K9 in 
the promoter region of Hif1a target genes to regulate nutrient response67. Additionally, Sirt6 
was reported to suppress gluconeogenesis by activating the acetyltransferase GCN5 and 
thereby indirectly regulate the activity of PGC-1α (a transcription factor of gluconeogenic 
genes)74. Knocking out Sirt6 was shown to abolish glucose homeostasis and upregulate 
glucose level and gluconeogenesis in muscle and fat tissues59. Like Sirt1, Sirt6 has been 
linked to longevity; its expression level decreases during aging in dermal fibroblasts, and 
overexpression of Sirt6 can extend the lifespan in male mice by ~15%75. Thus Sirt6 serves 
important roles in the control of metabolism and longevity. 
Sirt7 is a nuclear sirtuin and is involved in the regulation of ribosome biogenesis by 
promoting RNA polymerase I (Pol I)-dependent transcription of ribosomal DNA (rDNA)64, 76. 
Sirt7 is shown to interact with transcription factors and deacetylate the Pol 1 subunit PAF53 to 
enhance the interaction between Pol I and DNA, which in turn enhance pre-rRNA synthesis77. 
Moreover, rDNA transcription can be depressed during mitosis when Sirt7 is phosphorylated 
and resumes after mitosis due to the dephosphorylation of Sirt778. In addition, Sirt7 also 
contributes to the process of pre-rRNA maturation79. Notably, Sirt7 expression is correlated 
with cell proliferation and tumorigenesis. Sirt7 was ascribed to deacetylate histone H3 at 
position K18 to repress transcription of tumor suppressor genes, which in turn promotes 
tumorigenesis including hepatic, breast and thyroid cancer. In contrast, SIRT7 depletion was 
shown to inhibit cell proliferation and oncogenic transformation80. Recently, several studies 
have highlighted the function of Sirt7 in the regulation of metabolic homeostasis. SIRT7 was 
shown to restore metabolic homeostasis indirectly by deacetylating GABPβ1, a master 
regulator of nuclear-encoded mitochondrial genes, to activate the mitochondrial biogenesis81. 
Other reports on Sirt7 function include its role in the repression of ER stress (response to the 
accumulation of unfolded proteins) through its interaction with Myc to silence gene 
transcription related to ribosome biogenesis, the negative regulation of Hif1a and Hif2a 
activity, and the impact on lipid metabolism82. Even though Sirt7's in vivo function is majorly 
related to the deacetylase activity, but it only displays very weak deacetylase activity in vitro, 
as described for Sirt6. 
1.2.3 Sirtuin structure and catalytic mechanism 
Despite their different intracellular distribution and substrate specificity, all Siruins share a 
conserved catalytic core with yeast Sir243, 83. The conserved catalytic domain encompasses 
about 275 amino acids and is flanked by N- and C- terminal extensions, which differ in 
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sequence and length among isoforms (Figure 5A). The extensions offer a way to regulate 
subcellular localization, enzymatic activity and the interaction with regulator proteins51, 84. 
High-resolution crystal structures of apo or (co)substrate-bound forms of several Sirtuins have 
been published and contribute to our understanding of their catalytic mechanism. The overall 
structure of the Sirtuin catalytic core is conserved. It consists of two domains, a large α/β 
Rossman-fold domain for NAD+ binding and a small, structurally diverse domain containing 
a zinc-binding motif and a four-helix bundle absent in Sirt683. The zinc ion is located far away 
from the enzyme catalytic site, but seems to play a structural role, since any mutation in the 
zinc-binding motif lowering the zinc affinity was shown to destabilize the structure and 
therefore indicates a catalytic function. Unlike for other protein deacetylase, the zinc ion does 
not participate directly in catalysis to assist the hydrolysis reaction85. The two domains are 
connected by several loops that form an active site cleft in which both the acylated lysine and 
NAD+ bind (Figure 5B). The catalytic site is flexible and conformational changes occur upon 
Sirtuin binding to substrate protein or the cofactor. The NAD+ binding site contains three sub-
pockets, where the adenosine moiety of NAD+ binds to pocket A, the diphosphoribose group 
binds to pocket B and the nicotinamide group binds to pocket C86. NAD+ binding causes a 
conformational change of the so-called “cofactor binding loop”, the largest linking loop 
within the cleft between two domains, whose conformation is highly flexible in the absence of 
NAD+. It gets more ordered upon cofactor binding83. The acylated substrate binds to the cleft, 
forming a β-staple interaction between substrate main chain and β-sheets from both domains. 
The acylated lysine inserts into a narrow hydrophobic tunnel within the cleft, reorganizing the 
linking loops between the two domains and facilitating the formation of a more closed 
conformation83, 87. Additionally, the crystal structure of Sirt5 with a bound succinyl peptide 
reveals that the Tyr102 and Arg105 residues within the catalytic site of Sirt5 recognize the 
acyl group carrying a negatively-charged carboxylate52 (Figure 5C). Furthermore, the 
complex structure of Sirt6/myristoyl-peptide/ADPr revealed a Sirt6‐specific acyl channel to 
accommodate the long-chain fatty acyl group55 (Figure 5D). Notably, Sirt 1-3 were also 
identified to have long-chain deacylation activity in vitro, such as demyristoylation activity88. 
The crystal structures of Sirt2 and Sirt3 in complex with myristoylated peptides revealed that 
the myristoyl group occupies the cleft between two domains and demonstrates diverse 
orientation for Sirt2 and Sirt3 to avoid the clash with nearby helix bundle89, 90. Although Sirt 
1-3 displayed higher Km values with the myristoylated peptides than those of the acetylated 
peptides, the Kcat/Km for Sirt 1-3 demyristoylation is similar to that of their deacetylation88. 
Compared to Sirt 1-3, Sirt6 has a wider space for the myristoyl group due to the reduction of 
Introduction 
 - 13 - 
cofactor-binding loop and neighboring helix bundle, and the Kcat/Km value from Sirt6's 
demyristoylation to its deacetylation increase more than 300 fold55. 
 
Figure 5: Mammalian Sirtuins share a conserved catalytic core, but display different 
acyl group preference. (A) Primary sequence alignment of mammalian Sirtuins. (B) The 
complex structure of Sirt3/ AceCS2 peptide /carba-NAD+ (PDB ID 4FVT). The Rossmann-
fold domain (magenta), small domain (cyan) and the connecting loops (green) between the 
domains are shown in cartoon. The cofactor binding loop is highlighted in red. Carba-NAD+ 
(gray) and the acetyl-lysine of AceCS2 peptide in the active site are represented in sticks. (C) 
Close view of the succinyl-lysine peptide binding site in Sirt5’s active site. The ternary 
complex structure of Sirt5/ IDH2 peptide /carba-NAD+ (PDB ID 4G1C) is shown in gray 
cartoon, carba-NAD+ (gray), the succyl-lysine of IDH2 peptide (green) and the important 
residues for recognizing the specific acyl group are labeled in sticks, and polar interactions are 
indicated by dashed red lines. (D) Close view of Sirt6’s specific long chain acyl group 
binding channel. The ternary complex structure of Sirt6/H3K9 peptide /ADP-ribose (PDB ID 
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3ZG6) is shown in gray cartoon, ADP-ribose (gray), the myristoyl-lysine of H3K9 peptide 
(green) and the important residues for recognizing the specific acyl group are labeled in sticks. 
The catalytic mechanism of Sirtuins has been proposed to occur in two steps (Figure 6). In the 
presence of substrate and NAD+, the co-substrate binding loop becomes ordered and the 
catalytic site undergoes a major conformational change to a productive conformation, which 
comprises the rotation of the ribose sugar of NAD+ towards acylated lysine and the shift of 
acylated lysine carbonyl oxygen in close proximity to NAD+. The reaction begins with the 
replacement of nicotinamide (NAM) from NAD+ by the acyl oxygen and forms a 1’-O-
alkylamidate intermediate between acylated lysine and the ADP-ribose moiety, then the 
catalytic histidine activates the 2'-hydroxyl group of the NAD+ ribose and induces the 
nucleophilic attack on O-alkylamidate carbon to form a bicyclic intermediate, subsequently, a 
water molecule reacts with this bicyclic intermediate to complete the reaction and yield 
deacylated substrate and 2’-O-acetyl-ADP-ribose (2’-OAADPr)43, 91. Thus Sirtuins act as 
metabolic sensors to link NAD+ consumption with protein deacylation. 
 
Figure 6: Sirtuin deacetylation mechanism (Figure taken from Yu et al., 201692 with 
permission of PLOS ONE). 
1.3 Pharmacological modulation of Sirtuins 
1.3.1 Sirtuin activators 
Sirtuin-activating compounds (STACs) were first reported for Sirt1 (Figure 7A). The plant 
polyphenol resveratrol was identified as the first Sirtuin activator in a natural compound 
screen, and it has been shown to extend lifespan in yeast and metazoans as well as to promote 
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human cell survival in a Sirtuin dependent manner37. Biochemical studies identified that the N 
terminal sequence of Sirt1is required for resveratrol mediated activation and the relevant 
region was hence called STAC-binding domain (SBD)93, 94. Moreover, Sirt1 was described as 
the primary resveratrol target in vivo, supported by the finding that inactive Sirt1 mutants do 
not show the effects of resveratrol in primary cells93. However, resveratrol has only moderate 
potency against Sirt1. It also demonstrates off-target effects on other proteins and displays 
poor bioavailability, which makes it less suitable for pharmaceutical application95.. Therefore, 
high through-put screens were performed to identify further, more potent Sirt1 activators. 
Notably, new activators with different chemotypes were identified to activate Sirt1 through a 
common allosteric mechanism with resveratrol, and they showed EC1.5 values for activating 
Sirt1 nearly 1000 fold lower93  Biochemical and crystallographic studies reveal that synthetic 
STACs as well as resveratrol increase Sirt1 activity through binding to the SBD domain and 
rotate the domain on the top of the active site to stabilize the close conformation and enhance 
the binding of the substrate(Figure 7B, C). Although more detailed mechanistic information 
of how sirtuins can be activated still is lacking, the effects of synthetic STACs as Sirt1 
activators are currently being evaluated in clinical trials for anti-inflammatory drugs and the 
management of metabolic diseases37. 
Promising activators for the other Sirtuin isoforms, that lack Sirt1’s N-terminal activator 
binding domain, have been described only recently. 1,4-dihydropyridine (DHP)-derived 
compounds, and in particular the derivatives carrying a benzyl group at the N1 position were 
found to show activating effects on Sirt1, 2 and 3 in the Fluor-de-Lys assay. They induced a 
dose-dependent increment of mitochondrial density in murine C2C12 myoblasts, and reduce 
senescence in primary human mesenchymal stem cells (hMSC). However, the effect of these 
compounds was determined using the FdL assay and needs to be confirmed with 
physiological substrates96. Additionally, Honokiol has been demonstrated to enhance Sirt3 
expression and promote Sirt3 activity in vivo, but showed rather weak potency and non-
specific effects97. Moreover, activators using well-established assays on physiological 
substrates were described for Sirt6. For example, certain free fatty acids and endogenous fatty 
acid ethanolamides were reported to behave as dose-dependent activators of Sirt6-dependent 
deacetylation. They displayed competitive inhibition of Sirt6-dependent demyristoylation 
when on physiological peptide substrates, indicating that free fatty acids may occupy the 
binding site of myristoylated peptide in the enzyme’s long acyl binding channel88. 
Nevertheless, these compounds enhanced Sirt6 deacetylation activity only at very high 
concentrations (several hundred micromolar) and the interaction details are unknown. 
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Figure 7: Sirtuin activators work by improving the binding affinity of the substrate. A) 
Chemical structures of Sirtuin activators. B) The ternary complex structure of human 
Sirt1/carba-NAD+/ STAC-1 (PDB ID 4ZZJ) is shown in gray cartoon. The carba-NAD+ 
(yellow) and activator (cyan) are labeled in sticks. C) The ternary complex structure of human 
Sirt1/FdL peptide/ resveratrol (PDB ID 5BTR) is shown in gray cartoon. The FdL peptide 
(yellow) and activator (cyan) are presented as sticks. 
1.3.2 Sirtuin inhibitors 
Sirtuins have been shown to affect diverse physiological processes linked to aging and cancer, 
and therefore are considered potential molecular targets for the development of small 
molecule modulators to treat various age-related diseases and cancer. Several compounds 
have been identified to inhibit Sirtuins, but the binding sites and molecular mechanisms for 
many of these compounds still remain unknown. Many of them also show unfavorable 
properties for drug development such as low potency and poor specificity84, 98. Among the 
seven Sirtuin isoforms, mainly inhibitors of Sirt1 and 2 have been studied with regard to their 
promising therapeutic potential for neurodegenerative disorders. The isoform-specific areas in 
the C-pocket surrounding region have also exploited to generate highly selective Sirtuin 
inhibitors. The extended C-sites can be classified into three parts, namely ECS I-III (Figure 
8).84. For example, Ex-527 occupies the ECS I and shows higher potency against Sirt1 than 
Sirt2 and Sirt399, 100. ELT-11c occupies the ECS II and is characterized as the most potent 
inhibitor of Sirt1, Sirt2 and Sirt3 with IC50 values in the nanomolar range 101. 4′-bromo-
resveratrol occupies the ECS III and is inhibitor for Sirt1 and Sirt3102. More recently, novel 
deacylation functions for Sirt 4-7 have been identified52, 103 and enables the discovery of 
isoform selective chemical modulators. For example, Sirt5 was found to display more 
efficient demalonylase, desuccinylase and deglutarylase activities than its deacetylase 
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activity52,53. As controls, other Sirtuins do not deacylate the peptides containing malonyl, 
succinyl and glutaryl lysine. In addition, the thioacetyl-lysine peptides by substitution of the 
acyl oxygen with sulfur have been developed as mechanism-based inhibitors for Sirt 1-3 by 
forming a stalled S-alkylamidate intermediate104. Therefore, thioacyl-lysine peptides with 
chemical modifications at the N- and C-termini were exploited for the design of Sirt5's 
specific inhibitors. A thiosuccinyl-lysine H3K9 peptide was found to display significant 
inhibition potency against Sirt5's desuccinylase activity with an IC50 value of 5 μM, and to 
show no appreciable effect on Sirt1-3 at 100 µM105. Conversely, a thioacetyl-lysine H3K9 
peptide was potent on Sirt1-3 but did not inhibit Sirt5. Even more recently, one set of 
thioglutaryl-lysine peptide derivatives have been identified as the most potent Sirt5's specific 
inhibitors106. 
 
Figure 8: Structural information of Sirtuin inhibition by small molecules. A) Chemical 
structures of Sirtuin inhibitors. B) Structural overlay of the Sirt3/FdL peptide/ carba-NAD+ 
(gray cartoon, PDB ID 4FVT) with Sirt3/ELT-11c (PDB ID 4JSR), Sirt3/EX527 (PDB ID 
4BVH) and Sirt3/bromo-resveratrol (PDB ID 4C7B). The carba-NAD+ (yellow) and 
acetylated peptide (magenta) are shown in sticks format.  
Accumulating data suggest that inhibition of Sirt6 activity can be used within therapeutic 
approaches for some cancers, notably in the treatment of pancreatic cancer. However, as yet 
only few Sirt6 modulators with unfavourable characteristics are available, including poor 
efficacy, low solubility and bioavailability107, 108. Nicotinamide (NAM) acts as a pan inhibitor 
for Sirtuins because of its ability to rebind to the enzyme in the presence of product 
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intermediate and reform NAD+ by undergoing nicotinamide exchange in a non-competitive 
fashion109. In addition, Salicylate derivatives have been identified to inhibit Sirt6 with modest 
potency and isoform selectivity107,110. The catechin derivatives catechin gallate and 
gallocatechin gallate were identified to be the most potent Sirt6 inhibitors able to reduce 
Sirt6-dependent deacetylation in the single-digit micromolar range111, However they show 
wide effects on a broad variety of cellular targets112. TSA is an antifungal antibiotic and has 
been found to be a potent and selective inhibitor of Class I and II mammalian histone 
deacetylases (HDACs) with IC50 values in the low nanomolar range
113. Treating mammalian 
cells with TSA could halt the cell cycle in G1 and G2 phase, induce cell differentiation and 
repress progression of tumor cells in vitro114. TSA analogue Vorinostat has been approved by 
FDA for the treatment of cancer115. Recently, TSA has been demonstrated to exert isoform-
specific inhibition of Sirt6-dependent deacetylation by competing with the substrate rather 
than serve as a Zn2+ ion chelator116. However, the molecular mechanism of Sirt6 inhibition by 
TSA still awaits clarification. Although these compounds are not suitable as pharmacological 
inhibitor for Sirt6, understanding their binding interaction detail and the mode of inhibition 
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2 Aims of this Study 
2.1 Identify and characterize Sirt6 activating compounds 
Schlicker et al have identified a novel compound scaffold namely UBCS038/CSC38 as a Sirt6 
modulator from a virtual screenemploying the FdL assay117. The goal of this project was to 
characterize the activator binding site and elucidate the activation mechanism, and to identify 
more potent derivatives design UBCS038 derivatives with better potency and provide 
structural insights into Sirtuin 6 activation by small molecules. 
2.2 Biochemical and structural studies of quercetin-based compounds on 
Sirtuins 
It was demonstrated that quercetin can activate the deacetylase activity of Sirtuins and some 
of the quercetin derivatives were shown to potently inhibit Sirt6 instead of activation, but the 
molecular mechanism is not well clarified.32, 118. The aim of this project was to clarify the 
effect of quercetin-based compounds on Sirtuins and identify the compound binding site and 
modulation mechanism.  
2.3 Identify the mechanism of Sirtuin 6 inhibition by Trichostatin A 
In this study, we aimed to determining the crystal structure of the Sirt6/TSA complex to 
identify the inhibitor binding site and understand the inhibition mechanism to improve Sirt6 
inhibitor, which maybe also helpful for the development of Sirt6 activator. 
2.4 Enginner protein sequence of Sirt7 to facilitate crystallization 
Sirtuins have been identified to show different selectivity against acyl substrates52, which is 
dictated by the structural feature in the catalytic domain, but the crystal structure of the 
catalytic core of Sirt7 remains unknown. Thus, we want to reveal the catalytic mechanism of 
Sirt7 by biochemical and structural studies. Therefore we need to establish recombinant 
production of Sirt7 to obtain the required amounts of pure protein. 
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3 Results and discussion 
3.1 Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules 
3.1.1 UBCS compounds enhance Sirt6 deacetylase activity 
To verify the previously reported weak Sirt6 activating effect of UBCS038 in the error-prone 
FdL assay, we set out to identify a more potent compound by testing UBCS038 derivatives. 
Our collaborator generated a series of UBCS038 derivatives with a common feature of 
Pyrrolo-quinoxaline ring (Fig. 9A) and we tested all the 14 compounds in a coupled 
enzymatic assay. Several compounds showed activating effects on Sirt6 deacetylase activity, 
including UBCS039, UBCS058, UBCS059, UBCS060, UBCS061 and UBCS068, and the 
strongest effect was measured for UBCS039 (Fig. 9B). Titration with UBCS039 showed a 
concentration dependent activation with a maximum stimulation around 2-fold (Fig. 9C). The 
EC50 value of UBCS039 was around 40 µM, and we didn‘t observe any effect of this 
compound on the assay’s downstream enzymes in control reactions. We also assessed the 
effect of UBCS039 in a mass spectrometry-based deacylation assay with an acetylated human 
Histone H3 Aly9 peptide substrate, and we found that the deacetylase activity of Sirt6 
increased around 3.5-fold in the presence of 100µM UBCS039 (Fig. 9D). These results 
demonstrated that UBCS039 is able to directly stimulate Sirt6 deacetylase activity. In addition, 
we found that UBCS039 shows no measurable effects on Sirt6’s demyristoylation activity in 
the coupled enzymatic assay (Fig. 9E). To determine whether UBCS039 can stimulate other 
Sirtuin isoforms, we also tested the compound against Sirt1, 2, and 3 with acetylated substrate 
peptide, and Sirt5 with succinylated substrate peptide. Our results revealed that UBCS039 
exerts selective activation for Sirt6’s deacetylation activity and display no effects on the other 
Sirt1-3 deacetylase activities, but it can also promote the physiologically dominant function of 
Sirt5 (Fig. 9F). To identify whether the pyrrolo[1,2-a]quinoxaline compounds have any effect 
to stimulate Sirt6-dependent deacetylation activity upon physiological substrates, our 
collaborators performed western blot to analyze the effect of compounds on full-length 
histone proteins and complete HeLa nucleosomes. UBCS038 and UBCS039 at 100µM were 
found to significantly promote the deacetylation rate of H3K18Ac of both native substrates by 
Sirt6. The weak in vitro activator UBCS060 showed no effect on Sirt6-dependent H3K18ac 
deacetylation, and UBCS068 was observed to display variability in assays, likely owing to the 
lower solubility of this compound in the buffer solution. Our data demonstrate that the 
pyrrolo[1,2-a]quinoxaline-derived compounds can stimulate Sirt6-dependent deacetylation 
towards peptide substrates and native substrates (Fig. 9G). 
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Figure 9: UBCS compounds activate Sirt6-dependent deacetylation of peptide substrates 
and native substrates. A) Chemical structures of the compound library based on UBCS038. 
B) A panel of UBCS038 derivatives was tested for effects on Sirt6 deacetylase activity in the 
coupled enzymatic assay at concentrations of 20 and 80 µM. C) Titration of UBCS039 yields 
a concentration-dependent Sirt6 activation. D) The effect of UBCS039 on Sirt6-dependent 
deacetylation of an acetylated human Histone H3 Aly9 peptide substrate analyzed by a mass 
spectrometry-based assay. E) The effect of UBCS039 on Sirt6’s demyristoylation activity. F) 
Selectivity of UBCS039 (100 µM) was tested against human Sirt1-3 and 6 with an acetylated 
peptide substrate, and Sirt5 with a succinylated peptide substrate. G) Western blot analysis of 
the effects of compounds (100µM) on the Sirt6-dependent deacetylation of native histone H3 
lysine 18 from a histone protein preparation (left) and HeLa nucleosomes (right). 
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3.1.2 Sirt6's specific long acyl channel is identified as the activator binding site 
To analyze activator binding, we measured the interaction between Sirt6 and UBCS039 by 
microscale thermophoresis (MST).  As concentration dependent fluorescence quenching was 
observed with some compounds in label-free MST, subsequent thermophoresis measurements 
were done with FITC-labeled Sirt6. The dissociation constant of apo Sirt6 with UBCS039 
was determined to be 44 ± 12 µM, which is of the same order of magnitude as its EC50 value. 
The value of the dissociation constant is not significantly altered in the presence of 2 mM 
acetylated peptide substrate, which has a Km around 200 µM, or 1 mM ADP-ribose, an 
NAD+ derived moiety with a Kd of 38 µM, indicating that the interaction between Sirt6 and 
activator is independent from the binding of the peptide substrate or ADP-ribose. However, 
there is an order of magnitude drop of the binding affinity for UBCS039 in the presence of 
100 µM myristoylated peptide substrate (Kd=3.4 ± 0.9 µM), implicating Sirt6’s specific long 
acyl channel as activator binding site (Fig. 10A). We further demonstrated that the binding 
affinities of UBCS058 (Kd ~236 ± 49 µM) and UBCS068 (Kd ~467 ± 135 µM) are much 
weaker than for UBCS039, which is consistent with their less potent Sirt6 activation. 
Moreover, UBCS060 (Kd ~740 ± 391 µM) shows even weaker binding to Sirt6, consistently 
with its further decreased activation of Sirt6 on peptide substrates and native substrates (Fig. 
10B). These results indicated that UBCS compounds bind to Sirt6 in a ligand independent 
manner and display a binding behavior that is competitive with myristoylated peptide. 
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Figure 10: Crystal structure of the ternary complex of human Sirt6 with ADP-ribose 
and UBCS compounds. A) Binding of UBCS039 to apo-Sirt6 (■, Kd 44 ± 12 µM), in the 
presence of 2mM H3K9ac peptide substrate (○, Kd 26 ± 3 µM), 1mM ADP-ribose (△, Kd 38 
± 16 µM), or 100µM TNFα-Myr peptide (◇ , Kd > 400 µM ). B) Binding of UBCS 
compounds to Sirt6 in the presence of 2mM H3K9ac peptide: UBCS039 (◇, Kd ~44 ± 12 
µM), UBCS058 (●, Kd ~236 ± 49 µM), UBCS068 (฀, Kd ~467 ± 135 µM) and UBCS060 
(▲, Kd ~740 ± 391 µM).  C) Overall view of the ternary complex structure with human Sirt6 
(cartoon presentation), ADP-ribose (yellow sticks), and UBCS039 (cyan sticks). His133 at the 
active site is represented in sticks. D) Closer view of the Sirt6 activator complex. The surface 
of Sirt6 is colored according to electrostatic potential, and UBCS039 (cyan sticks) is covered 
with 2Fo-Fc density contoured at 1σ. E) Interactions between UBCS039 and human Sirt6, red 
dash line represents polar contact and the potential hydrogen bond. F) LigPlot of human Sirt6 
and UBCS039 interactions. G) Structural overlay of Sirt6 complexes with UBCS038 (gray), 
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UBCS039 (cyan), UBCS040 (green) and UBCS058 (magenta). H) Close view of the 
structures overlay of Sirt6 complexes with UBCS038 (gray) and UBCS040 (green), showing 
their interaction with the surface patch around Trp71/188. I) Chemical structures of activator 
derivatives, blue or red squares highlight the different positions of the nitrogen atom in the 
pyridine C-group. 
Since binding of an activator to Sirt6 appears to be independent of substrate and ligand 
binding, we crystallized Sirt6 in complex with ADP-ribose and then soaked the crystals with 
100 mM activator between 7 and 10 days to obtain Sirt6/activator complex structures. We 
solved the crystal structure of a ternary complex of Sirt6 with ADP-ribose and UBCS039 at a 
resolution of 1.87Å with Rwork and Rfree values of 19.6 % and 22.5 %, respectively. One 
UBCS039 molecule binds per protein molecule with well-defined electron density (Fig. 10C, 
D). The activator was identified to occupy a hydrophobic pocket and is exposed to the solvent 
through the exit channel of Sirt6’s catalytic core, which is distinct from the ADP-ribose 
binding site. The 3-pyridyl C-group of UBCS039 was found to insert into the hydrophobic 
pocket and form a polar contact, and likely hydrogen bond if protonated, with the peptide 
backbone oxygen of Pro62 through the nitrogen of its pyridine. In addition, the pyrrolo[1,2-
a]quinoxaline group of UBCS039 is located between Phe64/82/86 and Ile185 via hydrophobic 
interactions, and comes into close contacts with Met136/157 to possibly form methionine–
aromatic ring interactions (Fig. 10E, F).  
We also obtained the ternary complex structures of Sirt6/ADPr with UBCS038, UBCS040 
and UBCS058 at a resolution range of 1.97–2.10 Å by using the same procedure as described 
for UBCS039. The compounds occupy the same binding site as UBCS039 with well-defined 
electron density coverage. The pyrrolo[1,2-a]quinoxaline group of these compounds share the 
hydrophobic interaction with Sirt6 at the active site exit, albeit with different orientation in the 
tricyclic plane, likely due to the nature of the substitutions at the N5 (N-group) and C4 (C-
group) positions. These derivatives suggest that the 6-ring in the center of the tricyclic system 
in either saturated (UBCS038, UBCS039) or unsaturated format (UBCS058) presents a 
limited surface for interaction with protein. The binding of activators and their function are 
thus for the most part governed by substitutions at the N5 (N-group) and C4 (C-group) 
positions. Comparison with the complex structure of Sirt6/ADP-ribose/UBCS039 reveals that 
in spite of the different orientation of the tricyclic plane, the 3-pyridyl C-group of UBCS038 
and UBCS058 are found to bind in the same position inside the catalytic core as observed for 
that of UBCS039 (Fig. 10G). This similarity suggests that this pyridine C-group in the 
Results and discussion 
 - 25 - 
activators might play an important role for binding and function. This “C-group pocket” is 
composed of hydrophobic residues including Ile61, Pro62, Phe64/82/86, Val70, and Val115. 
Moreover, the potential hydrogen bond between the nitrogen atom at meta position of the 
pyridine ring and the peptide backbone oxygen of Pro62 seems important for high affinity and 
robust Sirt6 activation. When the pyridine nitrogen is shifted from meta to ortho position like 
in UBCS060, it will lose its ability to interact with the backbone oxygen of Pro62, explaining 
the lower Sirt6 binding affinity and potency of compound UBCS060 (Fig. 10I).  
The dominant effect of the pyridine C-group on binding to Sirt6 is highlighted by the complex 
structure of Sirt6 and UBCS038. The   3-(trifluoromethyl-) phenylsulfonyl moiety at the N5 
position of UBCS038 points towards the Sirt6 surface and forms interactions with a patch of 
residues near the entrance of the substrate binding channel, encompassing Trp71/188, Lys15, 
and Glu74. This interaction is enabled by a quinoxaline ring rotation by approximately 60 
degrees around the axis of the pyridine C-group following a slight translation. The pyridine C-
group is allowed to be placed into the same position as that of UBCS039 due to this switch 
(Fig. 10G). In comparison with the activator UBCS038, the distal ring of the hydroxynaphthyl 
moiety of the inactive compound UBCS040 is found to bind in the same position. This causes 
a huge rotation of the quinoxaline ring due to the limited interaction surface, which places the 
quinoxaline ring into the same position as that of the N5 substituent of UBCS038 but does not 
lead to activation (Fig. 10H). Thus the pyridine group at the C4 position provides the 
dominant contribution for the protein-activator interaction, while the quinoxaline ring and the 
N5 substituent also contributing to the binding albeit with weaker and less specific 
interactions. Therefore the quinoxaline ring and the substitutions at the N-group are 
considered to be prime candidates for further development aiming to improve compound 
performance, including solubility and potency. 
Comparison of the Sirt6/UBCS039 structure with the previously published Sirt6/myristoyl-
peptide structure (PDB ID 3ZG6) demonstrates that the UBCS compounds occupy a common 
region in the distal part of Sirt6’s specific catalytic pocket, which accommodates the long 
chain fatty acyl group of substrates (Fig. 11A). This location fits to the observation that the 
compounds specifically activate Sirt6’s deacetylation activity without affecting its 
demyristoylation activity. However, the compounds do not behave as strong competitive 
inhibitors toward myristoylated peptide substrates, likely due to their weak binding affinity in 
comparison to myristoyl peptides, as well as their limited solubility. On the other hand, in the 
presence of 100 µM myristoylated peptide substrate, the binding affinity of UBCS039 to Sirt6 
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decreases by more than one order of magnitude when compared to its value in the presence of 
acetylated peptide substrate. Our results thus demonstrate that our activators compete with the 
distal end of substrate myristoylation and thus differentially modulate Sirt6-mediated 
deacetylation and demyristoylation. Moreover, comparing Sirt6/UBCS039 structure with 
other published Sirtuin – activator complex structures revealed that the UBCS compound 
binding site within the Sirt6-specific acyl channel is not found in other Sirtuin isoforms, since 
it is covered by the cofactor binding loop and neighboring helix bundles in other Sirtuin 
isoforms like Sirt1 and Sirt5. These features are reduced to a short loop and single helix in 
Sirt6. Conversely, the activator binding site in other Sirtuin isoforms would be inaccessible in 
Sirt6, since it is covered by Sirt6’s N-terminus (Fig. 11B). 
 
Figure 11: The mechanism of substrate and Sirtuin isoform selection for Sirt6 activators. 
A) Structural overlay of the Sirt6/UBCS039 complex (gray cartoon/cyan sticks) with the 
Sirt6/myristoyl peptide complex (orange; PDB ID 3ZG6). B) Structural overlay of the 
Sirt6/activator complex (gray color) with Sirt1/ STAC1 (yellow color; PDB ID 4ZZI) and 
Sirt5/resveratrol (red color; PDB ID 4HDA). Dotted circle: Cofactor binding loop and 
neighboring helix bundle. 
Compared to the well-defined Sirt1 activators, the need to identify small molecule activators 
for other Sirtuin isoforms to treat aging-related disease is apparent. Our results identify 
isoform specific Sirt6 deacetylation activators with moderate potency, and reveal a novel 
activator binding pocket in Sirt6’s acyl binding channel, which is covered by the cofactor 
binding loop and neighboring helix bundle in other Sirtuin isoforms. The compounds only 
increase Sirt6's deacetylation activity and compete with Sirt6's deacetylation activity. 
Moreover, the compounds do not display apparent activation on Sirt1, Sirt2 and Sirt3, but 
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promote the Sirt5-dependent dessucinylase activity. In addition, comparison of Sirt6 apo and 
complex structures reveals no significant conformational changes, suggesting the compounds 
to mediate activation through mechanisms distinct from Srit1 and Srit5 modulation. Further 
investigation is needed to establish the activation mechanism of UBCS compounds. However, 
we present here for the first time synthetic small molecule Sirt6 activators and provide 
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3.2 Structural basis for Sirtuin6 activation and inhibition by quercetin and its 
derivatives 
3.2.1 Quercetin enhances Sirt6 deacetylase activity 
To elucidate the effect of quercetin on Sirt6-mediated deacetylation activity, we first tested it 
in a coupled enzymatic assay with the Histone H3-based acetylated peptide substrate H3K9Ac. 
Titration with quercetin showed a dose-dependent inhibition curve, but control reactions 
demonstrated that the activity of the assay’s downstream enzymes can also be inhibited by 
quercetin119 (Fig. 12B). Next, we tested the effect of quercetin in the FdL assay by using a 
peptide substrate derived from p53. Here, quercetin quenchs the FdL fluorescence signal 
rather than to inhibit Sirt6 deacetylation activity (Fig. 12C).  
 
Figure 12: Quercetin is established as an activator of Sirt6 dependent deacetylation. A) 
Chemical structures of quercetin and its derivatives. B) Quercetin titration yield concentration 
dependent inhibition in coupled enzymatic assay for Sirt6-dependent deacetylation (○) or 
control reaction without Sirtuin (▲). C) Dose-dependent effects of quercetin on the 
fluorescence signal in FdL assay for control reactions. D) Dose-dependent effects of quercetin 
(circle) and luteolin (triangle) on Sirt6 deacetylation activity. The data are presented as means 
± SD, n = 3. E) Western blots showing in vitro deacetylation activity of SIRT6 on purified 
Hela cell nucleosomes (left) or free histones (right), and activation by quercetin (5mM) 
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compared to DMSO vehicle negative control. Data are representative of 3 independent 
experiments. Relative acetylation on the indicated sites was determined by normalization to 
total H3 and control samples. 
To exclude assay artefacts, we therefore analyzed the effect of quercetin with a previously 
developed mass spectrometry-based assay by measuring the rate of deacetylated peptide 
formation from the substrate peptide H3K9Ac. The titration of quercetin and its analogue 
luteolin yield a concentration-dependent activation of Sirt6-mediated deacetylation with a 
higher than 2-fold maximum stimulation (Fig. 12D). The EC50 values of both compounds 
were around 1 millimolar, and we did not observe any evidence for the inhibition at lower 
concentrations described in previous reports. Thus, we speculate that the GST tag of Sirt6 
used in the previous study might cause the inhibition of Sirt6 in the presence of quercetin at 
low concentrations, due to the tight interaction between GST and quercetin. We further 
examined the effect of quercetin on Sirt6's physiological substrates, including nucleosomes 
purified from Hela cells and chicken. Quercetin was shown to activate the Sirt6-dependent 
deacetylation of H3K18Ac on nucleosomes and promote the deacetylation of H3K9Ac and 
H3K18Ac on free histones (Fig. 12E). 
To investigate the interaction between quercetin and Sirt6, we solved their complex structure 
by soaking experiments. The crystal structure of the Sirt6 catalytic domain in complex with 
quercetin was determined at a resolution of 1.84 Å. We identified the quercetin binding site in 
a hydrophobic pocket, mostly overlapping with the UBCS039 binding site (Fig. 13A, B). The 
two hydroxyl groups of quercetin’s catechol moiety form hydrogen bonds with the backbone 
oxygen of Pro62, and also make multiple water-mediated interactions with the distal 
backbone atoms, especially from residues Ala53, Val15 and Ile61, as well as with the side 
chain of Asp116 (Fig. 13B). The binding mode resembles the binding of the UBCS039 
pyridin and is thus likely that the catechol group functions as an anchor to bind at the bottom 
of the Sirt6 substrate binding channel. This binding mode appears to be a very important 
interaction pattern for Sirt6 modulators. In addition, the chromen-4-one group of quercetin 
forms hydrophobic interactions with Phe64/82/86 and Val70/115, and contacts Met136/157 
through a methionine–aromatic ring interaction.  
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Figure 13: crystal structure of a Sirt6/quercetin complex. A) Overall structure of human 
Sirt6 (cartoon presentation), ADP-ribose (yellow sticks), and quercetin (cyan sticks), His133 
at the active site is represented in sticks. B) Interactions between quercetin and human Sirt6, 
red dash lines represent the hydrogen bonds; atoms of quercetin are covered with 2Fo-Fc 
density contoured at 1σ. C) Protein surface of the Sirt6/quercetin complex colored according 
to the electrostatic potential. The ligand is shown as cyan sticks and overlayed with UBCS039 
(orange sticks). D) Structures overlay of Sirt6/ADPr/quercetin complex (gray cartoon, cyan 
ligand) with Sirt6/ADPr/myristoyl-peptide complex (orange cartoon, wheat peptide, PDB 
code 3ZG6). E) A quercetin titration shows dose-dependent inhibition of Sirt6 
demyristoylation. Data are shown as means ± SD (n = 3). F) Structural overlay of 
sirt6/ADPr/quercetin with Sirt1/ STAC1 (yellow color; PDB ID 4ZZI) and Sirt5/resveratrol 
(red color; PDB ID 4HDA). Dotted circle: Cofactor binding loop and neighboring helix 
bundle. 
A comparison between the Sirt6/quercetin complex and the Sirt6/UBCS039 complex structure 
described above indicates that the chromen-4-one group possesses a different plane 
orientation from the strong activator UBCS039 (Fig. 13C). This might lead to difference in 
potency against Sirt6. Moreover, structural alignment of the Sirt6/quercetin complex with the 
Sirt6/myristoyl-peptide complex reveals that quercetin also occupies the region 
accommodating the distal end of the myristoyl group of the substrate (Fig. 13D), indicating 
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that quercetin might inhibit the demyristoylase activity of SIRT6. We therefor analyzed the 
effect of quercetin on Sirt6 dependent hydrolysis of long chain fatty acyls in mass 
spectrometry-based assay by measuring the rate of myristoyl-TNFα substrate peptide 
deacylation. Titration of quercetin was found to inhibit Sirt6 dependent demyristoylation in a 
dose-dependent manner (Fig. 13E). Thus our data demonstrated that quercetin is able to 
stimulate Sirt6 dependent deacetylase activity and also inhibit the demyristoylase activity of 
SIRT6, likely using a mechanism related to that of UBCS039-mediated stimulation. Moreover,  
quercetin occupies the Sirt6-specific acyl channel, which is not present in the other Sirtuin 
isoforms (Fig. 13F). Our results thus implicate that this Sirt6 - quercetin interaction mode 
should be isoform-specific. 
3.2.2 Quercetin-based compounds show different effects on Sirt6 deacetylation 
Other flavonoids have been reported to alter SIRT6 activity. However, their effects vary 
depending on structure and chemical properties. For example, members of the flavanol family, 
lacking the keto group at position 4 of the C ring and the double bond occurring between 
carbons 2 and 3 of the C ring, were reported to inhibit Sirt6 deacetylase activity. Especially 
catechin gallate (CG) and gallocatechin gallate were identified as the most potent Sirt6 
inhibitors with IC50 values of 2.5 µM a d .4 µM respectively111. On the other hand, cyanidin 
was reported to be the most potent activator of Sirt6 with a maximal activation up to 55-fold, 
albeit with a moderate potency with an EC50 value of 460 µM
111. To understand the 
mechanism, we analysed the effect of these compounds in our mass spectrometry-based 
deacetylation assay. Titration of CG yielded a dose-inhibition curve with a much lower 
potency (IC50 80 ± 15 µM, Fig. 14A) compared to a previous report (IC50 2.5 ± 0.1 µM). In 
addition, we observed a dose-dependent activation of Sirt6 by treatment with cyanidin at a 
low compound concentration, from 9.76 to 78.12 µM (Fig. 14G). However, we failed to 
detect stimulation at high compound concentrations likely due to heavy compound 
precipitation, which might cause protein and peptide aggregation. 
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Figure 14: Quercetin derivatives can modulate Sirt6 activity with different functions.  
A) Dose-dependent effects of CG on Sirt6-mediated deacetylation activity. B) Overall 
structure of human Sirt6 (cartoon presentation), ADP-ribose (yellow sticks), and CG (cyan 
sticks), His133 at the active site is represented as sticks. C) Protein surface of the Sirt6/CG 
complex colored according to electrostatic potential; atoms of CG are embedded in 2Fo-Fc 
density contoured at 1σ.  D) Interaction of CG with Sirt6. Interacting residues are represented 
as sticks, and polar interactions are indicated by dashed red lines. E) LigPlot of the Sirt6 and 
CG interaction. F) Overlay of Sirt6 complexes with CG (cyan) and quercetin (gray), 
respectively. ADP-ribose (yellow) and His133 at the active site is represented in sticks. G) 
Dose-dependent effects of cyanidin on Sirt6 deacetylation activity, red spots indicate high 
concentrations. H) Interactions between cyanidin and Sirt6. Residues that interact with 
cyaniding are represented as sticks and polar interactions are indicated by dashed red lines. 
2Fo-Fc electron density for the ligand is contoured at 1σ. I) Protein surface of the 
Sirt6/cyanidin complex colored according to electrostatic potential. The ligand is shown as 
cyan sticks and superposed with quercetin (gray sticks).  
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To investigate the mechanisms of inhibition and activation, we obtained the ligand complex 
structures of Sirt6 with CG and cyaniding by soaking crystals of Sirt6/ADPr with the 
compounds overnight. The Sirt6/ADPr/CG ternary complex structures was determined at a 
resolution of 2.01 Å and revealed that one catechin gallate binds to each protein molecule 
with clearly defined electron density (Fig. 14B, C). CG was found to occupy the quercetin 
binding site at the end of the Sirt6-specific acyl binding channel, using the same binding 
space for its catechol moieties as quercetin, but with a rotation of the chromen-4-one scaffold 
with respect to the non-planar C ring and the additional trihydroxy benzoyl moiety on the 
carbon 3 of the C ring (Fig. 14D, E, F). Catechin gallate does not occupy the acetyl substrate 
binding site, but its catechol moiety partly overlaps with the NAM group of NAD+ in the C-
pocket. Therefore, CG could be assumed to perform inhibition in competition with NAD+. 
However, structural comparison of the Sirt6 complex with inhibitor and activator reveals that 
the catechol moiety of both compound types binds to the identical site, overlapping the 
binding site of the NAM moiety. Thus, we suggest that quercetin-based compounds bind to 
Sirt6 after nicotinamide release as similar to EX-527, and the variability in effects of 
quercetin-based compounds maybe due to the orientation of the chromene group or the 
substitution of a gallate group.  The ternary complex structures of Sirt6/ADPr/ cyanidin was 
determined at a resolution of 2.1 Å. Cyanidin was found to occupy the same binding site as 
quercetin (Fig. 14I), indicating a similar mechanism on activation, however, the compound 
only displayed good electron density coverage for  its catechol moiety while the chromen-4-
one group had poor density coverage, suggesting the presence of alternative conformations 
likely due to the lack of a keto group at the position 4 of the C ring (Fig. 14H). However, the 
mechanism of quercetin-based compounds requires further analysis. 
3.2.3 Isoquercetin acts as a Sirt6 activator and exhibits higher isoform specificity 
As quercetin and related polyphenols have been reported to affect the activity of other Sirtuin 
isoforms, we further tested it against human Sirt1-3 with acetylated substrate and Sirt5 with 
succinylated substrate. Notably, quercetin was found to inhibit all Sirtuins except Sirt6; for 
example, it caused the loss of deacetylase activity of Sirt2 to more than 80% upon treatment 
with 1250 µM quercetin (Fig. 15A). To understand why quercetin behaves differently in 
different Sirtuin isoforms, we obtained the crystal structure of a Sirt2/quercetin complex by 
soaking Sirt2/ADPr crystals with 100 mM quercetin for three days.  Together with Sandra, the 
structure was determined at a resolution of 2.23 Å, and revealed that a quercetin molecule 
binds at the symmetry-based dimer interface near the entrance to the active site (Fig. 15B), 
and exhibits distinct interaction with two symmetrical subunits. Quercetin is found to form π-
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π stacking with Tyr-114 and Phe-235, and forms hydrophobic contacts with Glu-116 and Glu-
120 from one subunit (Fig. 15C, D). It only exhibits a few contacts with the other monomer in 
a different rotated orientation. In comparison to the Sirt2 substrate complex structure, 
quercetin was found to occupy the volume accommodating the distal C-terminal residues of 
the substrate and thus sterically hinders its binding (Fig. 15E). To confirm the mechanism of 
inhibition, we next tested the competitive effect of quercetin in our mass spectrometry assay 
with concentrations of acetylated α-tubulin peptide in the range from 100 to 400 µM, and for 
each peptide concentration we tested quercetin at two different concentrations 312.5 and 1250 
µM. Our data revealed that quercetin induced Sirt2 deacetylation inhibition can be reduced by 
adding more acetylated α-tubulin peptide (Fig. 15F), consistent with the structural observation 
that quercetin binds to the active site entrance and blocks substrate binding. Moreover, 
overlays with the structures of other Sirtuin isoforms illustrate that this quercetin binding site 
is at the accessible surface area for some Sirtuin isoforms including Sirt1, Sirt3 and Sirt5 (Fig. 
15G), indicating that quercetin might use the same mechanism to regulate those Sirtuin 
isoforms. However, this quercetin binding site is inaccessible to Sirt6, since it is blocked by 
the N-terminal region of Sirt6 (Fig. 15H). 
 
Figure 15: The effect of quercetin on Sirtuins and the complex structure of Sirt2 with 
quercetin. A) Quercetin effects on deacylation by Sirtuin isoforms. B) Overall structure of 
human Sirt2 (cartoon presentation), ADP-ribose (yellow sticks), and quercetin (green sticks), 
His187 at the active site are represented as sticks. C) Close view of the Sirt2/quercetin 
complex. Residues interacting with quercetin are represented as sticks and quercetin (green 
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sticks) is covered with 2Fo-Fc density contoured at 1σ. D) LigPlot of Sirt2 and quercetin 
interaction. E) Structures overlay of Sirt2/quercetin complex (cyan cartoon, green ligand) with 
Sirt2/myristoyl-peptide complex (gold cartoon, wheat peptide in sticks, PDB code 4Y6O). 
Dotted circle: steric clash between substrate C-terminal and quercetin. F) Effects of quercetin 
on Sirt2 deacetylase activity against various substrate concentrations. G) Structural overlay of 
the Sirt2/quercetin complex (cyan cartoon, cyan ligand) with Sirt1 (red;PDB ID 5BTR), 
Sirt3(yellow;PDB ID 4HD8) and Sirt5 (magentas;PDB ID 4HDA). H) Structural overlay of 
the Sirt2/quercetin complex (cyan cartoon, green ligand) with Sirt6/quercetin complex (gray 
cartoon and ligand). Dotted circle: steric clash between Sirt6 N-terminus and quercetin. 
To support the development of highly selective Sirt6 modulators, we investigated the effect of 
quercetin derivatives. We found that isoquercetin retains the activating effect on Sirt6-
dependent deacetylase activity with a maximum stimulation of more than 2-fold, but did not 
significantly modulate Sirt1-3 deacetylase or Sirt5 dependent desuccinylase activity (Fig. 16A, 
B). Since isoquercetin showed improved selectivity for Sirt6, we tried to determine the 
complex structure of Sirt6/isoquercetin to obtain insights into the underlying molecular 
mechanism. An attempt to soak crystals with isoquercetin as described for quercetin initially 
failed. Lateron, we recognized that a PEG molecule occupied the active site with close 
proximity to the hydroxyl group at ring C of quercetin, which might prevent isoquercetin from 
binding to the Sirt6 specific acyl channel due to the weak potency of the compound and the 
high PEG concentration in the soaking condition. So we optimized the soaking condition by 
substituting PEG with ethylene glycol to obtain a crystal of the Sirt6/isoquercetin complex. 
The ternary complex structure of Sirt6/ADPr/isoquercetin was determined at a resolution of 
1.8 Å. We found that the quercetin group of isoquercetin binds to Sirt6 in the same manner as 
quercetin (Fig. 16C, D) and the additional sugar moiety of isoquercetin inserts into the Sirt6 
specific acyl channel with an overlap with the PEG molecule bound there (Fig. 16E). The 
electron density for the additional sugar moiety of isoquercetin is present but it is weaker than 
that for the quercetin group, likely due to its inherent flexibility, and it does not contribute to 
protein-ligand interactions. We further investigated the mechanism of isoquercetin for 
improved selectivity by placing the Sirt6/ADPr/isoquercetin complex structure on top of the 
Sirt2/ADPr/quercetin complex structure, and found that the sugar moiety of isoquercetin 
would form a steric clash with Tyr-114 of Sirt2 to improve selectivity for Sirt6 (Fig. 16F). 
Our results reveal that the sugar moiety can act as selector, which enables the ligand to bind 
into the Sirt6 specific acyl channel and negatively affects the interaction with other Sirtuin 
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isoforms. This indicates the C-ring hydroxyl group of quercetin as a potential site for 
modifications to enhance selectivity among Sirtuins. 
 
Figure 16: The effect of isoquercetin on Sirtuins and the complex crystal structure of 
Sirt6 and isoquercetin. A) Dose-dependent effects of isoquercetin on Sirt6 deacetylation 
activity. B) Effect of isoquercetin on Sirtuin isoforms. C) Close view of the Sirt6 and 
isoquercetin complex, interacting residues are labeled and isoquercetin (wheat sticks) is 
covered with 2Fo-Fc density contoured at 1σ. D) LigPlot of Sirt6 and isoquercetin interaction. 
E) Overlay of Sirt6/ADPr/isoquercetin complex (wheat ligand) with Sirt6/quercetin complex 
(cyan ligand), and the white line indicates the PEG molecule in the Sirt6/quercetin complex. F) 
Place isoquercetin (wheat ligand) on top of quercetin (cyan ligand) in the 
Sirt2/ADPr/quercetin complex structure (gray cartoon, side chains involved in quercetin 
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3.3 Structural basis of Sirtuin 6 inhibition by [the hydroxamate] trichostatin A 
3.3.1 Crystal Structure of Sirt6 in complex with trichostatin A 
We first studied the impact of Sirt6 substrate (acetyl peptide) and coligand (NAD+) on the 
Sirt6-TSA interaction in a binding assay using label-free MST. Our results revealed that the 
interactions between Sirt6 and TSA was enhanced in the presence of ADP-ribose (a fragment 
of NAD+), indicating that the complex of Sirt6-TSA can be stabilized by the nucleotide 
boundconformational state. Binding of TSA was not significantly altered by adding substrate 
peptide (Fig. 17B). We therefor determined the ternary complex structure of Sirt6/TSA/ADP-
ribose through soaking crystals of Sirt6/ADP-ribose complex with 10 mM compound 
overnight. Our complex structure revealed that TSA inserts into a hydrophobic pocket at the 
bottom of Sirt6 substrate binding channel, and the phenyl group is exposed to the solvent 
through the exit of the Sirt6’s catalytic core (Fig. 17C). The hydroxamate group binds in the C 
pocket, interacts with conserved residues there like the carboxamide part of nicotinamide, but 
apparently with improved affinity. The hydroxamate nitrogen of TSA forms a hydrogen bond 
with the side chain of a conserved residue in the C pocket (Asp116), and makes multiple 
water-mediated hydrogen bonds with the backbone oxygen of Ala53, Ile61 and Pro62, 
whereas the hydroxamate carbonyl oxygen interacts with the backbone amide of Val115 and 
Asp116. Moreover, the hydroxamate hydroxyl group is buried at the deep end of the C pocket, 
and forms additional hydrogen bonds with the side chain of residues Asp116, Asn114 and 
Ser56. It would be expected to greatly increase the relative binding affinity in comparison to 
the effect of the carboxamide of NAM (Fig. 17D, E, F). Additional TSA-Sirt6 interactions 
include the van der Waals contacts of the aliphatic linker of TSA and the 
diaminomethylphenyl moiety within the acyl channel of Sirt6, and it is likely to contribute to 
improving the binding affinity.  The aliphatic chain of TSA is observed with well-defined 
electron density coverage, and forms interactions with Phe64/80/86, Ile61, and Val70/115 in a 
largely hydrophobic cavity, which can accommodate the pyridine ring of nicotinamide. The 
phenyl ring of TSA is positioned away from the C pocket of the NAD+ binding site, and 
interacts with Val70 and Trp71. However, this moiety has poor density coverage, which is 
likely due to its flexibility (Fig. 17D). 
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Figure 17: Crystal structure of a Sirt6/TSA complex. A) Structures of NAM, TSA and 
SAHA. B) Binding of TSA to apo-Sirt6 (○, Kd 227 ± 35 µM), in the presence of 1mM ADP-
ribose (■, Kd 32.9 ± 5.9 µM), and in the presence of 1mM ADP-ribose and 1mM acetylated 
H3K9ac peptide substrate (◇, Kd 28.9 ± 8.2 µM). C) Overall structure of human Sirt6 
(cartoon presentation), ADP-ribose (yellow sticks), and TSA (cyan sticks), His133 at the 
active site is represented in sticks. D) Interaction of TSA with Sirt6. Interacting residues are 
labeled, and polar interactions are indicated by dashed red lines. 2Fo-Fc electron density for 
the ligand is contoured at 1σ. E) LigPlot of Sirt6 and TSA interaction. F) Overlay of the 
Sirt6/TSA complex (gray cartoon, cyan ligand) with a Sirt3/Ac-ACSpeptide/carba-NAD+ 
complex (PDB ID 4FVT, cartoon was hide, green carba-NAD+). G) Binding of TSA to apo-
Sirt6 (○, Kd 227 ± 35 µM) and in the presence of 10 mM NAM(▲, Kd 445 ± 66 µM). H) 
Structural overlay of the Sirt6/ADP-ribose/TSA complex (gray cartoon, cyan ligand) with a 
Sirt3/acetyl-ADP-ribose/Ex-527 complex (PDB ID 4BVH, yellow cartoon, magenta ligand). I) 
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Structures overlay of the Sirt6/ADP-ribose/TSA complex (gray color) with Sirt1 (yellow color; 
PDB ID 4IF6), Sirt2 (green color; PDB ID 3ZGV), Sirt3 (pink color; PDB ID 4FVT) and 
Sirt5 (red color; PDB ID 4G1C). Close view of the TSA (cyan ligand) binding site. Residues 
clashing with TSA are represented as sticks. 
Binding studies revealed that TSA does not compete with either peptide substrate or ADP-
ribose. However, decreased binding affinity of TSA for Sirt6 was observed in the presence of 
10mM NAM (Fig. 18G), suggesting that TSA can act as a Sirt6 inhibitor like NAM and 
EX527, which occupy the C pocket after NAM release and stabilize the intermediate complex 
(Fig. 18H). Compared to other Sirtuin structures, the Sirt6/TSA complex structure presents an 
isoform-specific binding motif for inhibitor. The TSA binding site comprises the unique acyl 
binding channel of Sirt6, which is occupied by the cofactor binding loop and neighboring 
helix bundles in other Sirtuin isoforms contain Sirt1,2 ,3 and 5. The distal part of the aliphatic 
chain and the dimethylaminophenyl moiety of TSA are observed to form steric clashes with 
other Sirtuin isoforms in this region (Fig. 18I), and therefore display significant selectivity in 
inhibition of Sirt6. Our results demonstrate that TSA is able to interact more extensively with 
conserved residues from the C pocket compared to NAM and thus enhance the interaction 
with Sirt6, whereas the extended cap group of TSA helps to convey isoform selectivity.  
3.3.2 Implication to develop class selective inhibitor based on TSA for HDACs 
To investigate how to develop the selectivity of TSA analogues against Class I/II HDACs and 
Sirtuins respectively, we placed the human HDAC7/TSA complex on top of the Sirt6/TSA 
complex and aligned them at the TSA binding site. While the hydroxamate groups and the 
aliphatic chains can be well overlaid, the phenyl groups are found to display different binding 
orientations. The phenyl group of TSA forms a clash with Trp71 of Sirt6 with the indicated 
orientation in the HDAC7 binding mode (Fig. 18A). The other way round, the different 
orientation of the phenyl group in HDAC7 is needed to prevent a major clash between TSA 
and the 1/2 loop as well as the 14 loop of HDAC7. SAHA has been identified as a 
specific inhibitor for Class I/II HDACs, and produces no effect on Sirtuins, in contrast to the 
inhibitory effect of its analogue TSA on Sirt6. To understand the mechanism underlying the 
specificity difference, we overlaid the complex structures of human HDAC2/SAHA and 
Sirt6/TSA. Notably, the aliphatic chain of SAHA serves to bind HDACs tightly like TSA, 
despite its high flexibility, likely due to energetically favourable binding conformation. 
However, the phenyl group of SAHA also forms a steric clash with Trp71 of Sirt6, according 
to the binding mode of SAHA with HDACs (Fig. 18B). Moreover, the long aliphatic chain of 
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SAHA is suggested to prevent the shift of the phenyl group like seen for TSA in its Sirt6 
complex to avoid a steric clash with Trp71 of Sirt6, and lead to the improved selectivity for 
HDACs over Sirt6. Thus our results suggest that modification of the phenyl moiety by placing 
a larger group there or by extension of the aliphatic chain length can increase the clash more 
with Sirt6 Trp71, and decrease the effect against Sirt6. Conversely, rigidification of the 
aliphatic chain length and the conformation of the phenyl moiety might optimize the potency 
of compound for Sirt6 and abolish the effect for Class I/II HDACs. 
 
Figure 18: Structural comparisons among different class HDACs. A) Compare the 
binding mode of TSA by placing the human HDAC7/TSA complex (PDB ID 3C10; protein 
displayed as surface, gold ligand) on the top of the Sirt6/TSA complex (gray cartoon, cyan 
ligand, side chains involved in TSA interactions are displayed in gray sticks). B) Compare the 
binding mode of TSA and SAHA by placing the human HDAC2/SAHA complex (PDB ID 
4LXZ; protein displayed as surface, red ligand) on the top of the Sirt6/TSA complex (gray 
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3.4 Identification of a subdomain of Sirt7 for crystallization. 
Sirt7 contains 400 amino acids and sequence alignments of Sirtuins reveal that its potential 
catalytic domain comprises residues 90-331. Both the N-terminal and C-terminal regions 
flanking the catalytic domain are identified to be low-complexity sequences. At the beginning, 
recombinant human Sirt7 constructs (residues 1-400, 59-356 and 81-356) were expressed 
using either the pOPIN-MBP vector system (encodes a cleavable N-terminal MBP tag) in 
E.coli BL21 (DE3) codon plus (residues 1-400) or using the pET-19b vector system (encodes 
an N-terminal his-tag) in E. coli C43 (DE3) Prep4 (residues 59-356 and 81-356). The 
recombinant proteins were expressed in an auto-induction system at 16°C for overnight. The 
purification was first performed by using Immobilized-metal affinity chromatography 
(IMAC), and the protein of interest was further purified by using cation exchange 
chromatography on a HiTrap SP-Sepharose Fast Flow column (GE Healthcare), followed by 
gel filtration using a Superdex 200 column (GE Healthcare). The N-terminal his tag attached 
to the residues 59-356 and 81-356 was cleaved by Tobacco Etch Virus (TEV) protease, and 
was purified by reverse affinity chromatography. In contrast, the MBP tag was kept for 
crystallization. However, when the oligomeric state of the recombinant proteins was evaluated 
in Blue Native Gel, they were found to form heavy aggregates and to remain in the sample 
well. In order to identify an improved protein subdomain for crystallization, the method of 
limited proteolysis was performed. Trypsin was selected for this experiment, various protease 
to protein ratios, reaction times and reaction temperatures were investigated. The digest was 
quenched by adding SDS PAGE loading buffer, and the result was displayed in SDS-PAGE. 
The N-terminal sequence of the subdomain was identified by protein sequencing and the C 
terminal sequence was determined by Mass spectrometry. Limited proteolysis of two Sirt7 
subdomains including residues 59-356 and 81-356 yielded the same fragment 134-348 (Fig. 
19A, B), but the treatment of Sirt7 full length generated two different fragments 134-388 and 
134-372 (Fig. 19C). Thus, new protein constructs were designed by starting with residue 100, 
121 or 134 and ending with various C terminuses, such as residue 356, 372 and 388. However, 
the expression of new constructs only yielded inclusion bodies and the secondary structure 
based sequence alignment of Sirtuins indicated that a conservative α-helix is located before 
residue 100, which is therefore thought to play an important role in stabilizing the overall 
structure. Next, we plan to extend N-terminus to include the potential helix and fusion protein 
to assist Sirt7 crystallization, and also consider expressing protein in different expression 
system like insect cell and mammalian cell. 
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Figure 19: SDS-PAGE of limited proteolysis performed at a trypin to Sirt7 ratio of 1:100. 
A) Limited proteolysis of Sirt7 subdomain 81-356 at room temperature (RT) and 4℃ with 
different incubation time. C indicates the sample of protein without proteolysis, and M 
refers to protein marker. B) Limited proteolysis of Sirt7 subdomain 59-356 at room 
temperature (RT) and 4℃ with different incubation time. C) Limited proteolysis of full 
length Sirt7 at room temperature (RT) and 4℃ with different incubation time. MBP refers 
to the Maltose-binding protein. D) Statistic of the fragment boundary analyzed by 
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Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules
Weijie You, Dante Rotili, Tie-Mei Li, Christian Kambach, Marat Meleshin, Mike Schutkowski,
Katrin F. Chua, Antonello Mai,* and Clemens Steegborn*
Abstract: Sirtuins are protein deacylases regulating metabo-
lism and stress responses, and are implicated in aging-related
diseases. Small molecule activators for the human sirtuins
Sirt1-7 are sought as chemical tools and potential therapeutics,
such as for cancer. Activators are available for Sirt1 and exploit
its unique N-terminus, whereas drug-like activators for Sirt2–7
are lacking. We synthesized and screened pyrrolo[1,2-a]qui-
noxaline derivatives, yielding the first synthetic Sirt6 activators.
Biochemical assays show direct, substrate-independent com-
pound binding to the Sirt6 catalytic core and potent activation
of Sirt6-dependent deacetylation of peptide substrates and
complete nucleosomes. Crystal structures of Sirt6/activator
complexes reveal that the compounds bind to a Sirt6-specific
acyl channel pocket and identify key interactions. Our results
establish potent Sirt6 activation with small molecules and
provide a structural basis for further development of Sirt6
activators as tools and therapeutics.
Sirtuins are NAD+-dependent protein lysine deacylases
regulating processes such as energy metabolism and stress
responses.[1] They have been implicated in aging and life-span
extending effects of caloric restriction (CR).[1, 2] Few potent
sirtuin inhibitors are available, but it is the activation of
sirtuins that can simulate CR effects and is considered
attractive for the treatment of several aging-related dis-
eases.[2, 3] Of the seven mammalian sirtuin isoforms (Sirt1–7),
Sirt1–3 feature strong deacetylase activities, while Sirt5 acts
primarily as a desuccinylase.[4] Sirt6 has much higher demyr-
istoylation than deacetylation activity on peptide substrates,[5]
but catalyzes robust histone deacetylation on complete
nucleosomes and chromatin.[6] Sirtuins bind substrates
between a Rossmann-fold and a Zn2+-binding subdomain of
their conserved catalytic core, burying the substrate acyl
group in a channel with isoform-specific features.[3a,4, 5] During
catalysis, the acyl oxygen forms an alkylimidate with ADP-
ribose produced from the co-substrate NAD+.[3a] After
rearrangement in a bicyclic intermediate, it is hydrolyzed to
yield deacylated polypeptide and 2’-O-acyl-ADP-ribose. The
sirtuin catalytic core is flanked by isoform-specific extensions
contributing to regulation and localization.[3a] Sirtuins show
protective effects against disorders such as cardiovascular
diseases (Sirt1 and Sirt3) and neurodegeneration (Sirt1).[1,3a]
Sirt6 contributes to metabolic adaptations and DNA homeo-
stasis, and it extends life-span in male mice and suppresses
aging phenotypes and cancer growth, for example, in the
pancreas.[7] Pharmacological Sirt6 activation is thus consid-
ered a treatment for cancer and other aging-related con-
ditions. Small molecule activation was first described for
Sirt1.[2] Although initially debated, it is now well documented
and potent, drug-like Sirt1 activators are available.[2, 8] A large
set of Sirt1 activators binds to a Sirt1-specific N-terminal
domain, which is assumed to induce a closure of the substrate-
containing active site and possibly a direct activator/substrate
interaction.[3a,8b,9] Few activating small molecule effects have
been described for the other sirtuin isoforms, all of which lack
the Sirt1 N-terminal domain. Sirt5 activation by resveratrol
was observed with the artificial substrate “Fluor-de-Lys”
(FdL), whose fluorophore mediates strong activator inter-
actions and might mimic part of the Sirt1 mechanism, and
with an acetylated protein, but not with its favored succinyl
substrate.[9] Weak and possibly non-specific activating effects
were also reported for the plant metabolite honokiol (Sirt3)
and fatty acids (Sirt6).[3a,10] The fatty acid effect appeared to
involve the acyl binding channel, but a structural character-
ization and the development of more potent and drug-like
compounds had to be awaited. Herein, we report the
discovery of pharmacological Sirt6 activators. The pyrrolo-
[1,2-a]quinoxaline-based compounds increase Sirt6-depen-
dent deacetylation of peptides and nucleosomes, and crystal
structures of Sirt6/activator complexes reveal their binding
site and provide a structural basis for drug development.
In an effort to identify scaffolds for isoform-specific
sirtuin inhibition, we recognized a weak, apparently stimula-
tory effect of the 4-(pyridin-3-yl)-5-((3-(trifluoromethyl)-
phenyl)sulfonyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline
UBCS038/CSC38 (1; Figure 1a) on Sirt6 using FdL assays.[11]
To clarify whether the compound indeed activates Sirt6, we
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first tested it in a coupled enzymatic assay (detecting the
sirtuin product NAM[12]) with an acetylated histone H3K9
peptide substrate. Adding 10 or 80 mm 1 caused weak
activation at the higher concentration (Figure 1b). To identify
more potent compounds, we generated a panel of 1 derivatives
2–14 (Figure 1a; Supporting Information, Figure S1 and
Methods). Testing their effects on Sirt6-dependent H3K9
peptide deacetylation yielded activation for several com-
pounds, with the highest activation for 4-(pyridin-3-yl)-4,5-
dihydropyrrolo[1,2-a]quinoxaline (7; UBCS039; Figure 1c).
Titration with 7 yielded a dose-dependent increase in Sirt6
activity, with a maximum & 2-fold stimulation and an EC50 of
38: 13 mm (Figure 1d). No effects were observed in control
reactions without sirtuin, or without the sirtuin co-substrate
NAD+ but spiked with NAM (Figure 1e), showing that the
activation effect is Sirt6-dependent. To further exclude assay
artifacts, we also tested the compound in a mass spectrom-
etry-based deacylation assay. Sirt6 showed the expected weak
deacetylation activity against the H3K9 peptide, and an& 3.5-
fold increase of this activity in the presence of 100 mm 7
(Figure 1 f). These results confirm that our pyrrolo[1,2-
a]quinoxaline derivatives enable direct Sirt6 activation.
Figure 1. Pharmacological Sirt6 activation. a) Chemical structures of 1 and selected derivatives (complete set: Figure S1). b) Activation of Sirt6-
dependent peptide deacetylation by 1. c) A panel of 1 derivatives tested at 20 and 80 mm for effects on Sirt6 deacetylase activity. d) 7 titration
showing concentration-dependent Sirt6 activation. e) Control reactions without sirtuin, in the absence and presence of 100 mm activator (left); and
without co-substrate NAD+ but spiked with 10 mm NAM (substrate for downstream enzymes), in the absence and presence of 100 mm activator.
f) Effect of 7 on Sirt6-dependent peptide deacetylation analyzed in a mass spectrometry-based assay. g) Western blot analysis of compound
effects, at 100 mm, on the Sirt6-dependent deacetylation of H3K18 in a histone protein preparation (left) and HeLa nucleosomes (right).
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We next analyzed the effects of our compounds on the
Sirt6-dependent deacetylation of physiological substrates,
namely full-length histone proteins and complete HeLa
nucleosomes. 1 and 7 showed robust activating effects on
Sirt6-dependent H3K18ac deacetylation of both substrates
(Figure 1g). No effect or weak stimulation was observed with
9, while 5 also activated Sirt6 but had slightly weaker and
more variable effects than 1 and 7 (Figure 1g), likely owing to
its lower solubility in aqueous buffers. However, we can
conclude that the pyrrolo[1,2-a]quinoxalines activate Sirt6-
dependent deacetylation of peptides and physiological pro-
tein substrates. We then tested whether 7-dependent activa-
tion is Sirt6-specific. The compound showed no statistically
significant effects on basal Sirt1, 2, and 3 deacetylation
activities (Figure 1h). For Sirt5, however, 7 caused a & 2-fold
increase in its desuccinylation activity. Compound 7 thus
shows specificity for Sirt6 among the deacetylase isoforms,
but can also stimulate the physiologically dominant Sirt5
activity.
We next studied the Sirt6 activator-binding site and
mechanism. Microscale thermophoresis binding experiments
revealed an affinity of 44: 12 mm for 7 to apo-Sirt6 (Fig-
ure 2a), comparable to its EC50 in activity assays. The Sirt6
affinity of 7 was not influenced substantially by the presence
of either 2 mm acetyl substrate peptide (Kd[7]= 26: 3 mm) or
1 mm ADP-ribose (Kd[7]= 38: 16 mm), a moiety of the co-
substrate NAD+ (Figure 2a), indicating that activator binding
is independent of these ligands. Consistent with their less
potent activation, 8 and 5 bound with lower affinities to Sirt6/
acetyl-H3K9 (236: 49 mm and 467: 135 mm, respectively),
and the compound 9 that only weakly activates Sirt6 showed
further decreased affinity (Kd& 740: 391 mm ; Figure 2b).
Analyzing Sirt6 activity in substrate titrations in the absence
and presence of the strongest binder, 7, suggested an increase
in turnover but allowed no definitive conclusions on KM and
vmax effects due to limited compound solubility and the low
in vitro Sirt6 deacetylation activity (Figure S2a).
The substrates and activator appear to bind independ-
ently, and we therefore attempted to solve Sirt6/activator
complex structures through co-crystallization and soaking
experiments in different combinations with peptide and
ADP-ribose. In this way, ternary Sirt6 complexes with
ADP-ribose and 1, 7, 14, or 8 could be solved at 1.87–
2.10c resolution (Table S1). All of the compounds occupied
the same Sirt6 catalytic core pocket, and the complex with 7 is
described in detail as a representative example. Sirt6/ADP-
ribose/7 was solved at 1.87c resolution, featured well-
defined electron density for the activator, and was refined
to Rcryst/Rfree values of 19.0/22.0% (Figures 2c,d and S2b;
Table S1). Compound 7 occupies a rather hydrophobic cone
at an active site exit, exposing the bottom of the pyrrolo[1,2-
a]quinoxaline to solvent (Figure 2c–e). The tricyclic system is
located between Phe82/86, Ile185, Trp71, and Met136/157,
possibly forming a methionine–aromatic ring interaction with
Met136 (Figures 2e and S2c). Comparison with the addi-
tional modulator complexes (Figure 2 f) shows that they share
the hydrophobic pyrrolo[1,2-a]quinoxaline/cone interaction,
albeit with variations in the compound plane orientation
within this hydrophobic aperture owing to their differing
substitutions at the N5 (N-group) and C4 (C-group) positions.
These variations indicate an only moderate interaction
through the tricyclic system, consistent with the limited
interaction surface complementarity and the fact that the
quinoxaline ring can be either saturated (1, 7) or unsaturated
(8), and it suggests an important contribution from the
substituents. Strikingly, the different binding orientations
position the identical 3-pyridyl C-groups of 1, 7, and 8 almost
identically in a binding pocket inside the catalytic core
(Figure 2 f). The hydrophobic “C-group pocket” is formed by
Ile61, Pro62, Phe64/82/86, Val70, and Val115 (Figures 2d,e
and S2c), and the pyridine nitrogen is in a position for a polar
contact and potential H-bond (in the case of a protonated
pyridine) to the backbone oxygen of Pro62. This similarity
suggests that the pyridine C-group serves as a major anchor-
ing point, and relevance for its interaction with Pro62 is
indicated by the fact that 9, in which the pyridine nitrogen is
shifted from the meta to ortho position, shows much lower
Sirt6 affinity and activation (Figures 1c, 2b). A dominant
binding contribution from the C-group is also indicated by the
Sirt6 complex with 1, which features an N-group in addition.
This 3-(trifluoromethyl-)phenylsulfonyl moiety is oriented
toward the protein surface and packed on a patch comprising
Trp71/188, Lys15, and Val70. This interaction, concomitant
with the conserved C-group interaction, is enabled through
a small shift and an & 608 rotation of the pyrrolo[1,2-
a]quinoxaline of 1 within the hydrophobic binding cone, and
an N-group-induced switch of the pyridine C-group into the
axial position (Figure 2g). Even the hydroxynaphthyl C-
group of the inactive compound 14 is placed with its distal ring
superposing with the pyridine moiety of the activators
(Figure 2g). This position of the larger C-group of 14 is
enabled by a substantially rotated compound orientation that
places its pyrrolo[1,2-a]quinoxaline on the Val70/Trp71 patch
that interacts with the 3-(trifluoromethyl-)phenylsulfonyl N-
group of 1. Thus, the compounds appear to bind dominantly
through the Sirt6 C-group pocket, and through weaker and
less specific interactions of pyrrolo[1,2-a]quinoxaline and N-
group to the Sirt6 exit surface. The latter compound moieties
thus seem amenable to major modifications for improving
solubility and potency, whereas our structures suggest only
smaller pyridine modifications for optimization of C-group
interactions.
Comparing Sirt6/7 with a Sirt6/myristoyl-peptide com-
plex[5] revealed that the activators occupy the Sirt6 channel
that accommodates distal parts of longer acyl substrates
(Figure 2h). As expected for competitive binding of myristoyl
group and activator, Sirt6 demyristoylation activity could not
be stimulated with 7 (Figure S2d), in contrast to its deacety-
lation activity. The compound also caused no significant
inhibition of demyristoylation, but with the 7 concentrations
attainable this weak binder cannot compete with the well-
binding myristoyl peptide. However, when added to 7 binding
assays, 100 mm myristoyl peptide weakened compound bind-
ing by at least one order of magnitude (Kd > 400 mm) as
compared to apo-Sirt6 and the acetyl peptide complex
(Figure 2a). We thus conclude that our activators and their
binding site enable differential modulation of Sirt6 deacety-
lation and demyristoylation activities.
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Figure 2. Structural and mechanistic characterization of Sirt6 activation. a) Binding of 7 to Sirt6 in the apo-state (&) and in the presence of
acetylated H3K9 peptide (*), myristoylated TNFa peptide (^), or ADP-ribose (~). b) Binding of Sirt6 activators in the presence of acetyl-H3K9
peptide: 7 (^), 8 (*), 9 (~), 5 (&). c) Overall structure of the complex between human Sirt6 (cartoon presentation), ADP-ribose (yellow sticks),
and the activator 7 (cyan sticks). The conserved catalytic residue His133 indicates the active site. d) Closer view of the Sirt6 activator complex.
The surface of Sirt6 is colored according to electrostatic potential, and 7 (cyan sticks) is overlaid with 2Fo@Fc density contoured at 1s. e) Binding
details for Sirt6 and 7. Interacting residues are labeled. ADP-ribose is shown in yellow, 7 in cyan. The dashed line indicates a potential polar
interaction. f) Overlay of Sirt6 complexes with 1 (gray), 7 (cyan), 14 (green), and 8 (magenta). g) Close-up of Sirt6 complexes with 1 (gray) and 14
(green), showing their interaction with the surface patch around Trp71/188. h) Overlay of the Sirt6/7 complex (gray/cyan) with a Sirt6/myristoyl
peptide complex (orange; PDB ID 3ZG6). i) Overlay of activator complexes of Sirt6 (gray; 7), Sirt1 (yellow; STAC1; PDB ID 4ZZI), and Sirt5 (red;
resveratrol; PDB ID 4HDA). Dotted circle: Cofactor-binding loop and neighboring helix bundle.
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Small-molecule activation is established for Sirt1 but
mechanistically only partially understood, and it is little
studied for other isoforms.[3a, 8] Our results establish potent,
pharmacological Sirt6 stimulation and reveal the activator-
binding pocket at a Sirt6-specific acyl channel opening. It is
covered by the cofactor-binding loop and neighboring helix
bundle in Sirt1 and Sirt5, but accessible in Sirt6 due to their
reduction to a short loop and single helix a3 (Figure 2 i).
Conversely, the activator site in the Sirt5/resveratrol com-
plex,[9] which is speculated also to contribute to Sirt1
activation,[3a, 8b] is an active site opening that is covered in
Sirt6 by its N-terminus (Figure 2 i). Thus, two different active
site openings are exploited in Sirt6 and Sirt1/5. Comparing
Sirt6/7 with several Sirt6 states (apo, ADP-ribose complex,
myristoyl peptide complex)[5, 13] reveals no significant con-
formational differences (Figure S2e). As for Sirt1/5, further
mechanistic details of Sirt6 activation thus remain to be
characterized. However, our identification of potent Sirt6
activators and of their Sirt6-specific binding sites provides an
excellent basis for further development of Sirt6 activators as
chemical tools and potential therapeutics.
Coordinates and structure factors for the Sirt6/compound
complexes have been deposited with the Protein Data
Bank (www.rcsb.org/pdb) under accession codes 5MGN
(UBCS038), 5MF6 (UBCS039), 5MFZ (UBCS040), and
5MPF (UBCS058).
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Materials and Methods 
Chemicals 
All chemicals were obtained from Sigma if not stated otherwise. Myristoyl-TNF peptide (Ac-
EALPK-(myristoyl-K)-TGG-amide) was prepared using standard solid-phase-peptide synthesis using 
a nosyl protected Lys6 building block. Subsequent to selective removal of the nosyl protecting group 
Lys6 was myristoylated on resin as described before [1]. All other HPLC-purified synthetic peptides 
were from GL Biochem (acetyl-H3K9: TKQTAR-(acetyl-K)-STGGKA; acetyl--tubulin: MPSD-
(acetyl-K)-TIG; acetyl-ACS2: TRSG-(acetyl-K)-VMR; succinyl-CPS1: RGVL-(succinyl-K)-EYGV). 
UBCS compounds were synthesized as described below and dissolved at 20 mM in DMSO to prepare 
stock solutions. 
 
Protein production and purification 
N-terminally his-tagged human Sirt6 constructs (residues 1-355, 1-318 and 13-308) were expressed 
using vector pQE80L.1 (internal pQE80 derivative with TEV cleavage site) in E. coli M15[pREP4] 
(construct 1-355) or vector pET151-D-TOPO in E. coli Rosetta2 (DE3) pLysS (shortened constructs). 
Proteins were expressed and purified essentially as described previously [2]. In brief, Sirt6 proteins 
were enriched through immobilized metal ion affinity chromatography (IMAC) on Talon resin 
(Clontech) or a HisTrap column (GE Healthcare), the tag removed using Tobacco Etch Virus (TEV) 
protease, and proteins subjected to reverse IMAC. The proteins were further purified through cation 
exchange chromatography on a HiTrap SP-Sepharose Fast Flow column (GE Healthcare), followed by 
gel filtration on a Superose 12 column (GE Healthcare) in 20 mM Na-HEPES pH 7.5, 100 mM NaCl, 




For coupled enzymatic peptide deacylation assays, the setup of Smith et al. [3] was used. Assays were 
performed in 100 l 50 mM Na-phosphate buffer pH 7.5, 5 % DMSO, 0.6 mM DTT, and 0.05 % (v/v) 
Tween 20, 200 µM acetylated histone H3K9 peptide, 500 µM NAD+, and 2.5 – 5.0 M Sirt6 enzyme. 
3 
 
Reactions with the indicated compound concentrations were run at 25 °C for 120 min and the 
absorption at 340 nm monitored in an Epoch 2 plate reader (BioTek). Reference measurements were 
done by adding the solvent DMSO without compound. For demyristoylation assays, myristoylated 
TNF peptide was used as the substrate. Control reactions were run with assay mixtures lacking either 
sirtuin enzyme, substrate peptide, or NAD+, and effects on downstream enzymes were tested by 
spiking control reactions with 5 – 40 M nicotinamide.  
For mass spectrometry-based deacylation assays, reactions containing 50 mM Na-phosphate 
buffer pH 7.5, 5 % DMSO, 0.1 % (v/v) Tween 20, 200 µM acetylated histone H3K9 peptide, 2 mM 
NAD+, and 5.0 M Sirt6 were incubated at 37 °C for up to 8 h and aliquots taken after several time-
points. Reactions were stopped by adding an equal volume 0.1 % trifluoro acetic acid and peptide 
deacetylation was quantified as described [4]. 
In vitro deacetylation reactions on histone and nucleosome substrates were performed as 
previously described [5], with minor modifications. Briefly, 2 μg of recombinant Sirt6 and 2 μg of Calf 
thymus histones (CTH; Sigma), or 5 μg mononucleosomes purified from HeLa cells were incubated in 
HDAC buffer (50 mM Tris-HCl pH 8.0, 2 mM NAD+, 150 mM NaCl) for 4 h (for CTH) or 80 min (for 
nucleosomes) at 30 °C. To test the effects of the compounds on Sirt6 activity, corresponding 
compound (100 M working concentration) or DMSO control was added before incubation. The 
reaction mixture was analyzed by western blotting and quantified using ImageJ.  
 
Binding assays 
Binding affinities were measured by using microscale thermophoresis (MST). Label-free 
measurements were done on a Monolith NT.label-free (NanoTemper Technologies) with 3 M Sirt6-
1-355 protein in 50 mM Na-phosphate buffer pH 7.5, 0.6 mM DTT, and 0.05 % (v/v) Tween 20, and 
10 % DMSO. After preincubation of protein and compound for 20min on ice, thermophoresis was 
analyzed at 25 °C with 20 % laser power and 15 % LED power. As some compounds induced a 
fluorescence quench in label-free MST, additional binding measurements were performed with labeled 
Sirt6 on a Monolith NT 115 (NanoTemper Technologies). Sirt6-1-355 was labeled by incubation with 
a 20 % molar fraction of FITC (Thermo Fischer) in 50 mM sodium borate, pH 8.5 at room temperature 
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for 30 min. Free dye was removed with a Nap5 column (GE Healthcare). 50 nM Sirt6 was 
preincubated with the compound for 20 min at room temperature in 50 mM phosphate pH 7.5, 0.05 % 
Tween-20 and 10 % DMSO, and thermophoresis was then measured at 25 °C at an excitation 
wavelength of 470 nm, emission wavelength of 520 nm, 10-20 % laser power and 15-20 % LED 
power. Binding curves were fitted with GraFit7 (Erithacus Software) with an equation for one binding 
site with background. All experiments were repeated at least twice. 
 
Crystallization and Structure determination 
Crystal structures of Sirt6 in complex with UBCS compounds were solved by crystallizing Sirt6-13-
308/ADP-ribose complex (stock solution: 10 mg/ml Sirt6-13-308, 10 mM ADP-ribose) at 20 °C in 
hanging drops with 1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7 as reservoir solution. 
Crystals appeared within 24 h and were subsequently soaked by adding 100 mM compound and 
incubation for one week. Crystals were transferred to cryoprotectant containing reservoir 
supplemented with 20% ethylene glycol, 2 mM compound, 10 % DMSO and 2 mM ADP-ribose, and 
then flash frozen in liquid nitrogen. 
Diffraction data were collected at 100 K at BL14.1 operated by Helmholtz-Zentrum Berlin 
(HZB) at the BESSY II electron storage ring (Berlin-Adlershof, Germany) [6]. Data were processed 
with X-ray Detector Software (XDS) [7] and programs of the CCP4 software suite [8]. Crystals 
belonged to space group P63 and showed merohedral twinning with twin fractions of 20 - 46 % as 
determined by an L-test. Structures were solved by Patterson searches (“molecular replacement”) 
using Molrep and the protein part of a Sirt6/ADP-ribose structure (PDB code 3K35) [9] as a search 
model. Structures were rebuilt in COOT [10] and subjected to amplitude-based twin refinement in 





Synthesis and analysis of 1/UBCS038 derivatives 
Melting points were determined on a Buchi 530 melting point apparatus and are uncorrected. 1H-NMR 
and 13C-NMR spectra were recorded at 400 MHz on a Bruker AC 400 spectrometer; reporting 
chemical shifts in δ (ppm) units relative to the internal reference tetramethylsilane (Me4Si). All 
compounds were routinely checked by TLC and 1H-NMR. TLC was performed on aluminum-backed 
silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light. Yields of 
all reactions refer to the purified products. All chemicals were purchased from Aldrich Chimica, Milan 
(Italy), and were of the highest purity. Mass spectra were recorded on an API-TOF Mariner by 
Perspective Biosystem (Stratford, TX, USA), and samples were injected with a Harvard pump using a 
flow rate of 5−10 μL/min, infused in the Electrospray system. Elemental analyses were performed 
with a PE 2400 (Perkin-Elmer) analyzer and have been used to determine purity of the described 
compounds, which is > 95%. Analytical results are within ± 0.40% of the theoretical values. 
The synthetic pathway for the preparation of compounds 1-15 is depicted in Scheme 1. 4-
(Hetero)aryl-4,5-dihydropyrrolo[1,2-a]quinoxalines 7, 9, 12, 14 were obtained from the condensation 
between the 1-(2-aminophenyl)pyrrole 15, prepared as reported,[12] and the proper commercial 
(hetero)aromatic aldehyde in dry EtOH in the presence of a catalytic amount of glacial acetic acid 
while heating at 50 °C. This reaction usually gave the correspondent oxidized side compounds 8, 10, 
and 13 in low yield, with the only exception of compound 11 that was obtained in high yield as unique 
reaction product. Final compounds 1-5 resulted from reaction of the compounds 7, 9, 12, and 14 with 
the proper commercially available benzenesulfonyl chloride in dry DCM in the presence of dry 
pyridine at room temperature, while compound 6 was obtained from the acylation reaction between the 
4-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxaline 12 and the benzoylchloride in dry DCM in the 




(a): Dry EtOH, cat. glacial AcOH, 50 °C; (b) PhCOCl, TEA, dry DCM, N2, rt; (c) R-SO2Cl, dry 
pyridine, dry DCM, N2, rt.  
 
General Procedure for the Preparation of the 4-Substituited-4,5-dihydropyrrolo[1,2-
a]quinoxalines (7, 9, 12, 14) and 4-Substituited-pyrrolo[1,2-a]quinoxalines (8, 10, 11, 13). 
Example: 4-(Pyridin-3-yl)-4,5-dihydropyrrolo[1,2-a]quinoxaline (7, MC3154, UBCS039)
[13]
 and 
4-(Pyridin-3-yl)pyrrolo[1,2-a]quinoxaline (8, MC3190, UBCS058).
[14] 
 
A solution of 1-(2-aminophenyl)pyrrole 15 (2.53 mmol, 400 mg), prepared as reported in literature, [12] 
and the commercial pyridine-3-carboxaldehyde (2.65 mmol, 284.4 mg) in dry ethanol (4 mL) was 
heated to 50 °C for 2h and 30 minutes in the presence of a catalytic amount of glacial acetic acid (15 
drops). After cooling to room temperature, the reaction was quenched with water (25 mL) and stirred 
for 1h. The resulting solid in suspension was then filtered off, washed with water and purified by silica 
gel column chromatography eluting with a mixture ethyl acetate/chloroform/hexane 1/12/3 v/v/v to 
afford the pure compound 7 as a white solid. By continuing the elution with the same solvent mixture 
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it was then collected the oxidized analogue 4-(pyridin-3-yl)pyrrolo[1,2-a]quinoxaline 8 as a white 
solid. mp 132-134 °C; yield 70%. 1H-NMR (CDCl3) δ 4.17 (s, broad, 1H, NH), 5.59 (m, 2H, C3-H and 
C4-H), 6.26 (t, 1H, C2-H), 6.77 (d, 1H, C6-H), 6.90 (m, 1H, C8-H), 6.99 (m, 1H, C7-H), 7.21 (s, 1H, 
C1-H), 7.22-7.37 (m, 2H, C9-H and pyridine-H), 7.82 (d, 1H, pyridine-H), 8.61 (d, 1H, pyridine-H), 
8.69 (d, 1H, pyridine-H). 13C-NMR (CDCl3) δ 53.9, 106.1, 110.3, 114.6, 114.8, 115.5, 119.8, 123.8, 
124.8, 125.4, 128.9, 135.6, 135.7, 137.1, 149.3, 149.8 ppm. Anal. (C16H13N3) Calcd. (%): C, 77.71; H, 
5.30; N, 16.99. Found (%): C, 77.76; H, 5.31; N, 16.93. MS (ESI), m/z: 248 [M + H]+. 
 




mp 152-155 °C; yield 22%. 1H-NMR (CDCl3) δ 6.97 (m, 1H, C3-H), 7.02 (m, 1H, C2-H), 7.46-7.54 
(m, 2H, C6-H and C8-H), 7.56-7.61 (m, 1H, C7-H), 7.94 (m, 1H, C1-H), 8.07-8.08 (m, 2H, C9-H and 
pyridine-H), 8.35 (m, 1H, pyridine-H), 8.80 (d, 1H, pyridine-H), 9.29 (s, 1H, pyridine-H). 13C-NMR 
(CDCl3) δ 107.9, 113.3, 113.9, 114.7, 123.2, 124.6, 125.1, 126.7, 127.6, 129.8, 133.8, 135.6, 135.8, 
149.0, 150.1, 150.9 ppm. Anal. (C16H11N3) Calcd. (%): C, 78.35; H, 4.52; N, 17.13. Found (%): C, 
78.39; H, 4.53; N, 17.08. MS (ESI), m/z: 246 [M + H]+. 
 
4-(Pyridin-2-yl)-4,5-dihydropyrrolo[1,2-a]quinoxaline (9, MC3148, UBCS060). 
  
mp 128-129 °C. 1H-NMR (CDCl3) δ 4.73 (bs, 1H, NH), 5.64 (s, 1H, C4-H), 5.88 (d, 1H, C3-H), 6.26 
(t, 1H, C2-H), 6.68 (dd, 1H, C6-H), 6.72-6.76 (m, 1H, C1-H), 6.84-6.88 (m, 1H, C8-H), 7.07-7.11 (m, 
2H, C7-H and C9-H), 7.16-7.17 (m, 1H, pyridine-H), 7.23-7.26 (m, 1H, pyridine-H), 7.49-7.53 (m, 
1H, pyridine-H), 8.50 (d, 1H, pyridine-H). 13C-NMR (CDCl3) δ 56.3, 100.5, 111.0, 114.7, 115.8, 
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116.1, 119.4, 121.6, 122.4, 124.7, 126.5, 131.9, 136.8, 138.5, 148.6, 158.7 ppm. Anal. (C16H13N3) 
Calcd. (%): C, 77.71; H, 5.30; N, 16.99. Found (%): C, 77.76; H, 5.31; N, 16.93. MS (ESI), m/z: 248 
[M + H]+. 
 




mp 104-105 °C. 1H-NMR (CDCl3) δ 6.90 (t, 1H, C3-H), 7.34-7.50 (m, 3H, C2-H, C7-H and C8-H), 
7.68 (d, 1H, C9-H), 7.81-7.85 (m, 2H, C6-H and C1-H), 7.95-7.96 (m, 1H, pyridine-H), 7.99 (m, 1H, 
pyridine-H), 8.35 (d, 1H, pyridine-H), 8.75 (d, 1H, pyridine-H). 13C-NMR (CDCl3) δ 110.5, 113.6, 
114.3, 114.4, 123.3, 124.2, 124.5, 125.1, 127.5, 127.9, 130.3, 135.6, 136.6, 148.8, 151.2, 156.3 ppm. 
Anal. (C16H11N3) Calcd. (%): C, 78.35; H, 4.52; N, 17.13. Found (%): C, 78.39; H, 4.53; N, 17.08. MS 
(ESI), m/z: 246 [M + H]+. 
 
4-(Pyridin-4-yl)pyrrolo[1,2-a]quinoxaline (11, MC3226, UBCS061).
[14-15] 
 
mp 196-199 °C. 1H-NMR (CDCl3) δ 6.97 (m, 1H, C3-H), 7.02 (m, 1H, C2-H), 7.53 (t, 1H, C6-H), 
7.61 (t, 1H, C8-H), 7.92-7.95 (m, 3H, C1-H, C7-H and C9-H), 8.07 (m, 2H, pyridine-H), 8.85 (m, 2H, 
pyridine-H). 13C-NMR (CDCl3) δ 108.1, 113.6, 114.3, 115.0, 123.0 (2C), 124.4, 125.9, 127.1, 128.3, 
130.3, 135.7, 146.2, 149.7 (2C), 151.3 ppm. Anal. (C16H11N3) Calcd. (%): C, 78.35; H, 4.52; N, 17.13. 
Found (%): C, 78.40; H, 4.53; N, 17.07. MS (ESI), m/z: 246 [M + H]+. 
 





mp 92-94 °C. 1H-NMR (CDCl3) δ 4.20 (bs, 1H, NH), 5.57 (s, 1H, C4-H), 5.61 (m, 1H, C3-H), 6.27 (t, 
1H, C2-H), 6.78 (dd, 1H, C6-H), 6.86 (m, 1H, C8-H), 7.00 (m, 1H, C7-H), 7.22 (m, 1H, C1-H), 7.36-
7.42 (m, 4H, benzene-H), 7.49-7.51 (m, 2H, benzene-H and C9-H). 13C-NMR (CDCl3) δ 56.2, 106.0, 
110.2, 114.5, 114.7, 115.5, 119.4, 124.9, 127.3 (2C), 128.4 (2C), 128.7, 128.9, 129.8, 135.9, 141.3 
ppm. Anal. (C17H14N2) Calcd. (%): C, 82.90; H, 5.73; N, 11.37. Found (%): C, 82.93; H, 5.74; N, 
11.33. MS (ESI), m/z: 247 [M + H]+. 
 




mp 87-89 °C. 1H-NMR (CDCl3) δ 6.93 (m, 1H, C3-H), 7.03 (m, 1H, C2-H), 7.50 (m, 1H, benzene-H), 
7.54-7.57 (m, 4H, C6-H, C7-H and benzene-H), 7.91-7.93 (d, 1H, C8-H), 8.02-8.08 (m, 4H, C1-H, 
C9-H and benzene-H). 13C-NMR (CDCl3) δ 108.6, 113.6, 114.0, 114.5, 125.2, 125.4, 127.1 (2C), 
128.3, 128.5 (2C), 129.1, 129.7, 130.2, 136.2, 138.4, 154.4 ppm. Anal. (C17H12N2) Calcd. (%): C, 
83.58; H, 4.95; N, 11.47. Found (%): C, 83.61; H, 4.96; N, 11.43. MS (ESI), m/z: 245 [M + H]+. 
 
1-(4,5-Dihydropyrrolo[1,2-a]quinoxalin-4-yl)naphthalen-2-ol (14, MC3180, UBCS040). 
 
mp 189-190 °C. 1H-NMR (CDCl3) δ 4.42 (bs, 1H, NH), 5.49 (m, 1H, C4-H), 6.22 (t, 1H, C3-H), 6.49 
(s, 1H, C2-H), 6.94-6.97 (m, 1H, C6-H), 7.08-7.12 (m, 2H, C8-H and naphthalene-H), 7.20-7.22 (m, 
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1H, C7-H), 7.25 (m, 1H, C1-H), 7.35-7.39 (t, 1H, C9-H), 7.42-7.48 (m, 2H, naphthalene-H), 7.83-7.87 
(m, 3H, naphthalene-H), 9.58 (bs, 1H, OH). 13C-NMR (CDCl3) δ 48.0, 104.8, 110.1, 114.7, 115.1, 
115.7, 116.7, 119.4, 123.1, 123.5, 124.2, 124.7, 126.4, 127.4, 129.2, 130.0, 130.1, 130.2, 134.4, 134.7, 
155.1.ppm. Anal. (C21H16N2O) Calcd. (%): C, 80.75; H, 5.16; N, 8.97. Found (%): C, 80.79; H, 5.17; 
N, 8.94 MS (ESI), m/z: 313 [M + H]+. 
 
General Procedure for the Preparation of 4-[(Hetero)aryl)]-5-((substituted)phenyl)sulfonyl) 4,5-
dihydropyrrolo[1,2-a]quinoxalines (1-5). Example: 4-(Pyridin-3-yl)-5-((3-





To a solution of 4-(pyridin-3-yl)-4,5-dihydropyrrolo[1,2-a]quinoxaline 7 (0.505 mmol, 125 mg) in dry 
DCM (4 mL) in the presence of dry pyridine (2.02 mmol, 0.16 mL), was added dropwise at 0 °C, 
under nitrogen atmosphere the commercial 3-(trifluoromethyl)benzenesulfonyl chloride (1.01 mmol, 
0.162 mL), and the resulting mixture was stirred at room temperature for 24h. After cooling to room 
temperature, the reaction mixture was diluted with DCM (25 mL) and washed with HCl 2N (2 x 5 mL) 
and brine (2 x 3 mL). The collected organic phases were dried and concentrated under vacuum to 
obtain a solid residue that was purified by silica gel column chromatography by eluting with a mixture 
ethyl acetate/petroleum ether 1/2.5 v/v to afford the pure compound 1 as a white solid; mp 169-170 
°C; yield 72%. 1H-NMR (CDCl3) δ 6.14 (m, 2H, C3-H and C4-H), 6.64-6.66 (m, 2H, C2-H and C6-
H), 7.14-7.20 (m, 3H, C1-H, C7-H and C8-H), 7.26-7.32 (m, 2H, C9-H and pyridine-H), 7.39 (m, 1H, 
benzene-H), 7.47 (s, 1H, benzene-H) 7.53 (d, 1H, pyridine-H), 7.59 (d, 1H, benzene-H), 7.75 (d, 1H, 
benzene-H), 8.37 (bs, 1H, pyridine-H), 8.43 (d, 1H, pyridine-H). 13C-NMR (CDCl3) δ 66.8, 109.1, 
113.7, 114.1, 118.5, 122.6, 122.8, 123.0, 124.3, 126.3, 128.3, 129.3, 129.5, 130.6, 131.1, 131.3, 131.5, 
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132.6, 134.9, 135.5, 140.1, 147.3, 150.3 ppm. Anal. (C23H16F3N3O2S) Calcd. (%): C, 60.65; H, 3.54; F, 
12.51; N, 9.23; S, 7.04. Found (%): C, 60.70; H, 3.55; F, 12.49; N, 9.22; S, 7.03. MS (ESI), m/z: 456 
[M + H]+. 
 
5-(Phenylsulfonyl)-4-(pyridin-3-yl)-4,5-dihydropyrrolo[1,2-a]quinoxaline (2, MC3178, 
UBCS041). 
 
mp 183-185 °C. 1H-NMR (CDCl3) δ 6.13-6.16 (m, 2H, C4-H and C3-H), 6.68-6.70 (m, 2H, C2-H and 
C6-H), 7.13-7.16 (m, 5H, C1-H, C7-H, C8-H, C9-H and benzene-H), 7.23-7.28 (m, 3H, benzene-H), 
7.32-7.36 (m, 1H, benzene-H) 7.56 (d, 1H, pyridine-H), 7.76 (d, 1H, pyridine-H), 8.37 (m, 1H, 
pyridine-H), 8.42 (d, 1H, pyridine-H). 13C-NMR (CDCl3) δ 66.8, 103.6, 111.2, 115.7, 118.5, 120.6, 
122.4, 123.7, 125.2, 127.6 (2C), 128.3, 128.5, 129.2 (2C), 131.5, 133.8, 134.9, 137.2, 138.2, 149.3, 
150.7. ppm. Anal. (C22H17N3O2S) Calcd. (%): C, 68.20; H, 4.42; N, 10.85; S, 8.27. Found (%): C, 





mp 144-147 °C. 1H-NMR (CDCl3) δ 6.10 (m, 1H, C4-H), 6.12 (m, 1H, C3-H), 6.62 (m, 2H, C2-H and 
C6-H), 7.12-7.21 (m, 6H, C1-H, C7-H, C8-H, C9-H and benzene-H), 7.27-7.29 (m, 2H, benzene-H), 
7.38-7.40 (m, 1H, benzene-H) 7.46 (m, 1H, benzene-H), 7.57-7.59 (m, 1H, benzene-H), 7.73 (d, 1H, 
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benzene-H). 13C-NMR (CDCl3) δ 69.5, 103.6, 111.0, 115.7, 118.2, 120.6, 122.4, 122.8, 125.2, 126.3, 
126.7, 126.9 (2C), 128.2, 128.8 (2C), 129.2, 129.4, 130.4, 130.7, 131.5, 132.2, 138.8, 139.9.ppm. 
Anal. (C24H17F3N2O2S) Calcd. (%): C, 63.43; H, 3.77; F, 12.54; N, 6.16; S, 7.05. Found (%): C, 63.49; 
H, 3.78; F, 12.52; N, 6.15; S, 7.04. MS (ESI), m/z: 455 [M + H]+. 
 
4-Phenyl-5-(phenylsulfonyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline (4, MC3188, UBCS065). 
 
mp 202-205 °C. 1H-NMR (CDCl3) δ 6.09 (m, 1H, C4-H), 6.14 (m, 1H, C3-H), 6.65 (s, 1H, C2-H), 
6.68 (m, 1H, C6-H), 7.10-7.28 (m, 12H, C1-H, C7-H, C8-H, C9-H and benzene-H), 7.31-7.35 (m, 1H, 
benzene-H), 7.75 (d, 1H, benzene-H). 13C-NMR (CDCl3) δ 69.4, 103.7, 111.2, 115.9, 118.1, 120.3, 
122.4, 125.2, 127.6, 127.8, 128.0 (2C), 128.5 (2C), 128.8 (2C), 128.9 (2C), 129.3, 131.7, 133.9, 138.3, 
138.7 ppm. Anal. (C23H18N2O2S) Calcd. (%): C, 71.48; H, 4.69; N, 7.25; S, 8.30. Found (%): C, 71.52; 
H, 4.70; N, 7.24; S, 8.29. MS (ESI), m/z: 387 [M + H]+. 
 
1-(5-((3-(Trifluoromethyl)phenyl)sulfonyl)-4,5-dihydropyrrolo[1,2-a]quinoxalin-4-
yl)naphthalen-2-ol (5, MC3291, UBCS068). 
 
mp 141-143 °C. 1H-NMR (CDCl3) δ 6.30 (m, 1H, C4-H), 6.71 (m, 1H, C3-H), 6.95 (t, 1H, C2-H), 
7.24-7.35 (m, 3H, C6-H, C8-H and naphthalene-H), 7.39-7.55 (m, 6H, C1-H, C7-H, C9-H and 
naphthalene-H), 7.65 (d, 1H, benzene-H), 7.75-7.78 (m, 2H, naphthalene-H and benzene-H), 7.82 (m, 
1H, benzene-H), 7.88 (d, 1H, benzene-H), 7.99-8.00 (d, 1H, naphthalene-H). 13C-NMR (CDCl3) δ 
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64.7, 107.8, 111.9, 114.2, 115.4, 117.7, 118.2, 122.4, 122.6, 123.1, 123.5, 125.1, 126.3, 126.5, 128.2 
(2C), 128.5, 129.1, 129.3, 129.5, 130.0, 131.1, 131.5, 131.8, 134.3, 135.2, 139.8, 155.0 ppm. Anal. 
(C28H19F3N2O3S) Calcd. (%): C, 64.61; H, 3.68; F, 10.95; N, 5.38; S, 6.16. Found (%): C, 64.63; H, 
3.69; F, 10.92; N, 5.37; S, 6.18. MS (ESI), m/z: 521 [M + H]+. 
 
Preparation of Phenyl(4-phenylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)methanone (6, MC3217, 
UBCS066).  
 
To a solution of 4-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxaline 12 (0.333 mmol, 82 mg) in dry DCM 
(3 mL), in the presence of TEA (1.83 mmol, 0.25 mL), was added dropwise at 0 °C benzoylchloride 
(1.332 mmol, 0.15 mL), and the resulting mixture was stirred at room temperature for 3h and 30 
minutes. At the end of the reaction, the solvent was removed under vacuum and the residue was 
suspended in water and then extracted with ethyl acetate (4 x 10 mL). The collected organic phases 
were washed with brine (2 mL), dried, and concentrated under reduced pressure to provide a crude 
residue that was purified by a silica gel flash chromatography (SNAP 25, Biotage Isolera One™) 
using a linear gradient of ethyl acetate (5% to 15%) in petroleum ether, giving the expected compound 
6 as a white solid. mp 150-152 °C; yield 82%. 1H-NMR (CDCl3) δ 6.34 (m, 1H, C4-H), 6.48 (m, 1H, 
C3-H), 6.72 (m, 1H, C2-H), 7.10 (m, 1H, C1-H), 7.16-7.21 (m, 6H, aromatic-H), 7.27-7.33 (m, 4H, 
aromatic-H) 7.38-7.43 (m, 4H, aromatic-H). 13C-NMR (CDCl3) δ 59.2, 111.0, 115.7, 117.3, 125.7, 
126.9 (2C), 127.8 (2C), 128.5 (2C), 128.8 (2C), 128.9, 129.3, 129.9, 131.9, 132.1, 134.9, 138.2, 138.6, 
139.2, 142.1, 168.1 ppm. Anal. (C24H18N2O) Calcd. (%): C, 82.26; H, 5.18; N, 7.99. Found (%): C, 





Supplementary Table 1: Diffraction data and refinement statistics for Sirt6/ADP-ribose/activator 
complexes. 
 
 Sirt6/1 Sirt6/7 Sirt6/14 Sirt6/8 
Data collection     
Space group                 P 63 P 63 P 63 P 63 
Cell dimensions 
a, b, c (Å) 
 
91.9, 91.9, 145.4 
 
91.3, 91.3, 144.3 
 
91.4, 91.4, 144.2 
 
91.4, 91.4, 144.2 








Rmeas 20.3 (110.3) 14.0 (132.0) 16.1 (109.5) 13.0 (96.0) 
I / I 8.7 (2.3) 12.2 (1.9) 12.9 (2.3) 14.1 (2.3) 
Completeness (%) 99.8 (99.0) 99.8 (99.1) 99.7 (98) 99.6 (97.3) 
Redundancy 11.3 (11.5) 10.3 (10.2) 11.4 (11.6) 11.3 (10.7) 
Twin fraction (%) 0.44 0.20 0.46 0.24 
     
Refinement     
Resolution (Å) 45.93-2.07 45.65-1.87 45.68-2.10 45.69-1.98 
No. reflections 40233 53308 37793 45143 
Rwork / Rfree 14.4/19.2 19.0/22.0 16.7/20.8 15.7/18.5 
No. atoms     
    Protein 4309 4353 4353 4345 
    UBCS ligand 32 38 24 38 
    ADP-ribose 72 72 72 72 
    Solvent 143 238 97 264 
B-factors     
    Protein 32.1 32.8 39.3 33.4 
    UBCS ligand 70.0 45.9 54.7 42.9 
    ADP-ribose 21.8 22.6 28.0 23.5 
    Solvent 35.1 36.3 46.6 38.1 
R.m.s. deviations     
    Bond lengths (Å) 0.024 0.022 0.023 0.021 
    Bond angles () 2.41 2.32 2.45 2.24 








Code Assay Code Structure mp (°C) 
recryst.  
System[a] % yield 
1 MC3163 UBCS038 
 
165-168 °C A 72 
2 MC3178 UBCS041 
 
183-185 °C A 78 
3 MC3196 UBCS064 
 
144-147 °C A 76 
4 MC3188 UBCS065 
 
202-205 °C A 81 
5 MC3291 UBCS068 
 
141-143 °C B 75 
6 MC3217 UBCS066 
 
165-168 °C A 82 
7 MC3154 UBCS039 
 
132-134 °C A 70 
8 MC3190 UBCS058 
 
152-155 °C B 22 
16 
 
9 MC3148 UBCS060 
 
128-129 °C A 72 
10 MC3155 UBCS059 
 
104-105 °C A 19 
11 MC3226 UBCS061 
 
196-199 °C C 86 
12 MC3179 UBCS063 
 
92-94 °C D 70 
13 MC3225 UBCS062 
 
87-89 °C D 23 
14 MC3180 UBCS040 
 
182-183 °C E 77 
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ABSTRACT: Protein lysine deacylases comprise three zinc-dependent families
and the NAD+-dependent sirtuins Sirt1−7, which contribute to aging-related
diseases. Few Sirt6-specific inhibitors are available. Trichostatin A, which belongs
to the potent, zinc-chelating hydroxamate inhibitors of zinc-dependent deacylases,
was recently found to potently and isoform-specifically inhibit Sirt6. We solved a
crystal structure of a Sirt6/ADP-ribose/trichostatin A complex, which reveals
nicotinamide pocket and acyl channel as binding site and provides interaction
details supporting the development of improved deacylase inhibitors.
■ INTRODUCTION
Sirtuins form class III of the protein lysine deacylase family
(also called histone deacetylases, HDACs) and regulate, for
example, chromatin homeostasis and energy metabolism.1
They require NAD+ as an essential cosubstrate, rendering them
metabolic sensors, and they have been implicated in aging-
related dysfunctions.1 Mammals have seven sirtuin isoforms
(Sirt1−7), with Sirt1, -6, and -7 being primarily localized in the
nucleus. Sirt1 is the best characterized isoform, acts as
deacetylase of histones and transcription factors, and is
modulated by a variety of small molecules and used as
therapeutic target for inflammatory diseases.1,2 Several bio-
logical Sirt6 functions are also established, but details of its
activity and regulation and Sirt6-specific modulators are
lacking.2,3 It associates with chromatin, modulates histones,
transcription factors, and DNA repair proteins and thereby
regulates gene expression and chromosome maintenance.3
Sirt6 supports longevity in male mice, suppresses aging
phenotypes, and promotes proliferation of several cancer
types,3 and small molecule Sirt6 modulators are thus sought for
functional studies and therapy.
Sirt6 comprises the conserved sirtuin catalytic core of ∼270
amino acids and small N- and C-terminal extensions that
contribute to chromatin association.4 The sirtuin core consists
of a Rossman-fold subdomain and a small, more variable Zn2+-
binding module, with the active site located between them.5
During catalysis, the cosubstrate’s nicotinamide (NAM)
moiety is placed in the so-called C-site for replacement of its
glycosidic bond by a new bond to the substrate acyl oxygen,
yielding an alkylimidate intermediate.6,7 Rearrangement in a
bicyclic intermediate and subsequent hydrolysis result in the
products deacylated peptide and 2′-O-acyl-ADP-ribose. Small-
er variations in the substrate sites lead to isoform-specific
substrate sequence and acyl preferences.8−10 Its particular
small Zn2+-binding module and cofactor-binding loop render
Sirt6’s acyl pocket rather wide and extended, allowing it to
hydrolyze long chain acylations such as myristoylation more
efficiently than acetylations in vitro.10,11 This Sirt6 activity
regulates TNF-α secretion, but a broader relevance of this
activity and of Sirt6’s low mono-ADP-ribosylation activity
remains to be confirmed.3,10 Sirt6 deacetylates histones and
other target proteins efficiently in vivo, however, and the
molecular reason for this discrepancy remains to be clarified.3
Few Sirt6 modulatory compounds are available. Fatty acids
activate Sirt6-dependent deacetylations at high micromolar
concentrations, and the flavonoid quercetin at millimolar
levels.12,13 More potent activation was achieved with synthetic
pyrrolo[1,2-a]quinoxalines, which bind to Sirt6’s acyl channel
exit, and with the quercetin derivative cyanidin.13,14 Sirt6 is
inhibited by the pan-sirtuin inhibitor NAM (Figure 1A), which
can rebind to the sirtuin/alkylimidate complex to regenerate
substrates (base-exchange reaction).7 The NAM related
pyrazinamide appears to inhibit Sirt6 more specifically but
with low (millimolar) potency.15 Salicylate derivatives and
docking derived compounds show slightly improved Sirt6
potency (IC50 ≥ 89 μM),
16,17 and the quercetin derivatives
catechin gallate and gallocatechin gallate were reported as first
potent small molecule Sirt6 inhibitors (IC50 = 3−5 μM) but
affect various targets.13,18 Cyclic peptides can also potently
inhibit Sirt6 but with limited selectivity.19 Recently, potent
Sirt6 inhibition was further described for trichostatin A (TSA;
Figure 1A).20 TSA and related hydroxamates, such as
suberoylanilide hydroxamic acid (SAHA, vorinostat; Figure
1A), inhibit class I and II HDACs by chelating their catalytic
Zn2+ ion.21 TSA induces cell cycle arrest and potently inhibits
proliferation of breast cancer cells, and the closely related
SAHA has been FDA approved for the treatment of T-cell
lymphoma.21−23 While sirtuins also feature a Zn2+ cofactor, it is
remote from the active site, fully coordinated, and serves a
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structural function, rendering the TSA effect on Sirt6
surprising.5,20 Activity assays indeed indicated that TSA
appears to inhibit Sirt6 through competition with the acetyl
substrate rather than by chelating its Zn2+ ion.20 TSA potency
against Sirt6 (Ki = 2−5 μM) is about 2−4 orders of magnitude
lower than against class I/II HDACs, but it is still the most
potent known Sirt6 inhibitor and shows no significant effects
on Sirt1−3 and Sirt5.20 Molecular details of Sirt6 inhibition by
TSA thus would provide insights in a potent and isoform-
selective Sirt6 inhibitor scaffold. Interestingly, the related
SAHA had no effect on Sirt6,20 indicating that small scaffold
variations enable selectivity for class I/II HDACs. Other
modifications of this scaffold will likely also enable to
specifically target sirtuins.
To exploit TSA scaffold and binding site for Sirt6 inhibitor
development, we characterized the Sirt6 inhibition by TSA
through binding assays and crystal structure analysis of a Sirt6/
ADP-ribose/TSA complex. We find that TSA binds to Sirt6’s
acyl channel extension, which explains its isoform specificity.
Binding is supported by ADP-ribose and noncompetitive with
acetyl substrate, indicating that active site closure supports
TSA binding. The inhibitor’s hydroxamate group occupies the
C-site and mimics NAM interactions, revealing a novel moiety
for exploiting this site and a scaffold for concomitantly
occupying NAM site and acyl channel extension. These results
Figure 1. Crystal structure of a Sirt6/ADP-ribose/TSA complex. (A) Chemical structures of NAM, TSA, and SAHA (vorinostat). TSA carbons are
numbered for referencing. (B) Binding of TSA to apo-Sirt6 (Kd = 227 ± 35 μM) or in the presence of 1 mM ADP-ribose (Kd = 33 ± 6 μM) or in
the presence of 1 mM ADP-ribose and 1 mM acetylated H3K9 peptide (Kd = 29 ± 8 μM). (C) Overall structure of Sirt6 in complex with ADP-
ribose (yellow) and TSA (cyan). (D) TSA interactions with Sirt6. Ligand and interacting residues are shown as sticks, colored according to atom
type. The ligand is overlaid with 2Fo − Fc electron density contoured at 1σ. (E) Scheme of the interactions between Sirt6 and TSA. (F) Overlay of
the Sirt6/ADP-ribose/TSA complex (gray cartoon, cyan ligand) with a Sirt3/acetyl-peptide/carba-NAD+ complex (PDB code 4FVT; protein and
peptide hidden, carba-NAD+ in green).
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provide molecular insights in potent and isoform-selective Sirt6
inhibition and will support further development of inhibitors
for Sirt6, other sirtuins, and other HDAC families.
■ RESULTS
Crystal Structure of a Sirt6/TSA Complex. To identify
TSA’s Sirt6 binding site and inhibition mechanism, we aimed
for solving a crystal structure of a Sirt6/TSA complex. For this
purpose, we first analyzed whether the two Sirt6 substrates,
acetyl peptide and NAD+, influence the TSA interaction.
Binding measurements using microscale thermophoresis
revealed that the ADP-ribose fragment of NAD+, which
suffices for inducing nucleotide binding site closure, supports
TSA binding and that adding substrate peptide has no
significant effect on inhibitor affinity (Figure 1B). We thus
soaked crystals of a Sirt6/ADP-ribose complex with TSA and
solved the structure of the trimeric complex by molecular
replacement phasing (Table 1). The Sirt6/ADP-ribose/TSA
complex was refined at 1.7 Å resolution to Rcryst/Rfree values of
15.5%/18.4% and revealed one TSA molecule bound per
protein monomer (Figure 1C). The inhibitor is positioned in
the Sirt6 substrate acyl binding channel, with its phenyl group
oriented toward the acyl channel exit and exposed to solvent
(Figure 1D,E). The hydroxamate group occupies the C-site,
which normally accommodates the NAM moiety of NAD+
(Figure 1D−F). It mimics and possibly even improves the
interactions with the carbamide-binding motif of the sirtuin C-
site. Nitrogen and carbonyl oxygen of the hydroxamate overlay
perfectly with the NAM carbamide and thus show the same
interactions (Figure 1F). The carbonyl oxygen interacts with
the backbone nitrogens of Val115 and Asp116, and the
nitrogen forms a hydrogen bond to Asp116, a possible polar
contact to Asn114, and water-mediated hydrogen bonds to the
backbone oxygens of Ala53, Ile61, and Pro62. The
hydroxamate’s additional hydroxyl group is oriented deeper
into the carbamide recognition pocket and forms additional
hydrogen bonds to Asp116, Asn114, and Ser56 (Figure 1E,F),
which are likely to contribute significantly to the higher affinity
of TSA (Ki(NAM) against Sirt6, 0.45 mM; IC50 for other
sirtuins, 0.02 to several mM).24,25
The aliphatic linker of TSA is bound in a hydrophobic
region that also accommodates the NAM pyridine moiety and
interacts with Phe64/82/86, Ile61, and Val70/115 (Figure
1D,E). The TSA phenyl ring is oriented toward the acyl exit
and positioned between Val70, Trp71, Met157, with one face
of the aromatic ring and the complete dimethylamino group
exposed to solvent (Figure 1D,E). In addition to this
incomplete shielding of hydrophobic compound surfaces
from solvent, the plane of the keto group is significantly
distorted and the oxygen rotated out of the phenyl plane.
These distortions are necessary to avoid a clash with Trp71,
and compound modifications relieving this strain should
improve Sirt6 affinity further (see discussion). However, the
larger interaction interface through TSA’s extended linker and
additional diaminomethylphenyl moiety as compared to NAM
likely also contribute to its already higher affinity. In particular
the linker seems relevant, since it is well-defined by electron
density, while the diaminomethylphenyl moiety is hardly
defined and likely flexible (Figure 1D).
Inhibition Mechanism and Implications for Sirtuin
Inhibitor Development. Our structure shows that TSA
occupies the C-site, which might suggest that it competes with
NAD+ (Figure 1F). No TSA/NAD+ competition was observed
in activity assays,20 however, similar to the behavior of the pan-
sirtuin inhibitor NAM and the Sirt1 inhibitor Ex527. NAM
inhibits via rebinding to the C-site of the long-lived alkyl
imidate intermediate complex and re-formation of substrates,
and Ex527 binds to the C-site after NAM dissociation to block
product release.7,26 A TSA binding titration to Sirt6 in the
presence of 10 mM of the low-affinity ligand NAM indeed
revealed weak but statistically significant competition with
isolated NAM (Figure 2A). Our structure further shows that
TSA interacts extensively with Sirt6’s short cofactor binding
loop (around Pro62) and α3 (Figure 1D), which undergo
rearrangements upon nucleotide binding.27 We thus propose
that TSA acts similar to NAM and Ex527 (Figure 2B) by
occupying the C-site after NAM release, consistent with the
requirement of the NAD+ fragment ADP-ribose for tight TSA
binding, the competition with NAM and lack of competition
with NAD+, and the binding mode in the structure. It causes
the reported peptide competition20 indirectly, by inducing a
conformation of cofactor-binding loop and nucleotide that
would create clashes with the substrate acyl.
TSA inhibits HDACs orders of magnitude stronger than
Sirt6, but as the most potent and specific Sirt6 inhibitor
known, it can nevertheless provide important information for
Sirt6 inhibitor development. Compared to NAM, TSA shows
increased affinity due to more extensive interactions with the
C-site’s carbamide pocket and its larger interaction interface.
Interactions in the highly conserved C-site are useful for
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affinity but less suitable for isoform specificity. The TSA
extensions thus should provide the information of how to
achieve selectivity for Sirt6 or also other sirtuin isoforms.
Analyzing an overlay of the Sirt6/ADP-ribose/TSA complex
with structures of Sirt1, -2, -3, and -5 indicates that the TSA
phenyl group and its position are keys to its specificity (Figure
2C). The moiety is oriented into the acyl channel exit and
packed on its hydrophobic rim (Figure 1D,E). This region is a
unique Sirt6 feature and covered by more extended cofactor
binding loops and neighboring helix bundles in other sirtuin
isoforms, leading to clashes, e.g., with Sirt1-Met296, Sirt2-
Ile118, Sirt3-Ile179, or Sirt5-Phe101 (Figure 2C).
The directly phenyl-connected part of the TSA linker (C5−
7; Figure 1A) contributes to these selectivity-mediating
interactions directly (e.g., clashes with Sirt1-Ile316, Sirt2-
Leu103, Sirt3-Leu195, Sirt5-Arg105) and through positioning
of the dimethylaminophenyl moiety (Figure 2C). The
proximal linker part (C2−4), in contrast, occupies the binding
region for the NAM pyridine group, which is conserved among
sirtuins and can mainly be exploited for affinity but not
selectivity (Figures 1F and 2C).
Our isoform comparison thus indicates that TSA mod-
ifications in the proximal linker region can further improve
general sirtuin affinity and that modifications in the distal
linker and terminal dimethylaminophenyl moiety can improve
Figure 2. TSA inhibition mechanism and specificity. (A) Binding of TSA to apo Sirt6 (Kd = 227 ± 35 μM) or in the presence of 10 mM NAM (Kd
= 445 ± 66 μM). (B) Overlay of the Sirt6/ADP-ribose/TSA complex (gray cartoon, cyan ligand) with a Sirt3/acetyl-ADP-ribose/Ex-527 complex
(PDB code 4BVH, yellow cartoon, magenta ligand). (C) Overlay of the Sirt6/ADP-ribose/TSA complex (protein as surface, TSA in cyan) with
Sirt1 (yellow; PDB code 4IF6), Sirt2 (green; 3ZGV), Sirt3 (pink; 4FVT), and Sirt5 (red; 4G1C). Examples for residues clashing with TSA are
shown as sticks. (D) Overlay of TSA complexes of Sirt6 (gray cartoon, cyan ligand) and HDAC7 (PDB code 3C10; protein displayed as surface,
gold ligand). (E) Overlay of Sirt6/TSA (gray cartoon, cyan ligand) and HDAC2/SAHA complexes (PDB code 4LXZ; protein displayed as surface,
red ligand). (F) Overlay of Sirt6/TSA (gray cartoon, cyan ligand) with Sirt6/UBCS039 (PDB code 5MF6; protein hidden, magenta ligand).
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sirtuin isoform selectivity (see also discussion); they can
further abrogate activity against class I/II HDACs (see below).
Implications for Development of Specific HDAC
Inhibitors. Hydroxamate-based HDAC inhibitors were
assumed to be specific for class I/II HDACs, and several
family members are in clinical trials or have entered the clinic,
in particular also SAHA.21,23 Indeed, SAHA is specific for
HDACs, in contrast to the closely related TSA with its Sirt6
inhibitory effect.20 To analyze the molecular basis of these
specificities and differences, we compared our Sirt6/ADP-
ribose/TSA complex with a human HDAC2/SAHA and a
human HDAC7/TSA complex, respectively, by overlaying
them based on an optimized superposition of their ligands
(Figure 2D,E). TSA hydroxamate and linker of the HDAC7
complex overlay well with the Sirt6/TSA ligand, but a different
orientation of the TSA dimethylaminophenyl group is caused
mostly by different torsions along the C5−6 bond. The
different orientation in HDAC7 is necessary to avoid clashes
with its α1/α2 loop and α14, which embrace the distal
compound group like forceps. Rigidifying this compound
section in its Sirt6-bound, HDAC7-incompatible conformation
thus would be an approach to abrogate HDAC7 activity and to
achieve Sirt6 specificity. In fact, overall structure and this
HDAC7 binding site feature are similar in other HDAC
isoforms,21 and stabilizing the Sirt6-bound conformation thus
will generally prevent HDAC effects. Reinforcing this notion,
the HDAC2/SAHA ligand can also be overlaid with Sirt6/TSA
for hydroxamate and proximal linker and deviates for the distal
part in the same way as the TSA in HDAC7, reflecting that the
HDAC binding groove for the distal compound part is
generally narrower than in Sirt6 and kinked. Notably, the
SAHA ligand overlays well with the HDAC7-bound TSA
despite its higher degree of rotational freedom, illustrating that
this conformation is required for HDAC binding. We assume
that the HDAC ligand conformation is also energetically
favorable, with the TSA carbonyl oxygen in plane with the
phenyl group and the TSA/SAHA carbonyl/carbamide mostly
in planar conformation, which should contribute to the higher
potency against HDACs. However, in contrast to the tight
packing of the ligands’ phenyl ends in the HDAC complexes,
Sirt6 provides a wide funnel for the distal compound part
(Figure 1D, Figure 2D,E). It would in principle allow for a
variation of orientations, but it also limits the binding
interactions that can be formed simultaneously. Also, the
HDAC2/7 binding mode is prevented in Sirt6 due to a clash
between the SAHA/TSA phenyl group and Sirt6-Trp71.
Adding groups to the distal inhibitor end thus appears
attractive to prevent activity against Sirt6, and shortening or
modifying this part might improve Sirt6 inhibition (see
discussion). In fact, the additional amino bridge between
inhibitor chain and phenyl group in SAHA might contribute to
its higher selectivity for HDACs over Sirt6 via this mechanism:
It prevents a TSA-like orientation of the phenyl group that
avoids clashes with Sirt6-Trp71. Another factor that might
contribute to TSA’s higher Sirt6 affinity compared to SAHA is
its two methyl groups branching off from the carbon chain and
interacting with hydrophobic Sirt6 patches.
■ DISCUSSION AND CONCLUSIONS
Despite Sirt6’s physiological relevance and huge interest in
small molecule modulators, few compounds have been
described, all of which lack the combination of potency,
specificity, and bioavailability required for pharmacological
applications.1,2,28 The most potent inhibition was so far
described for quercetin derivatives, which show pleiotropic
effects.18 For isoform-specific Sirt6 inhibition, NAM deriva-
tives were proposed.15 NAM can inhibit with medium potency
(IC50 = 20−200 μM) through a base-exchange reaction or with
low potency (IC50 millimolar) through NAD
+ competition,
depending on isoform and substrate acyl.7,25 The NAM
derivatives pyrazinamide and pyrazinoic acid showed only low
potency effects, rendering them nonsuitable for pharmaco-
logical applications despite a certain Sirt6 specificity.15 The C-
site inhibitor Ex527 shows higher potency (IC50 against Sirt1,
∼1 μM) but only weak selectivity caused by different kinetics
of acetyl-ADP-ribose formation, which is required as
coligand.26 However, our complex structure reinforces the
idea to exploit the conserved sirtuin C site for specific Sirt6
inhibition based on a new compound class and binding mode.
The TSA hydroxamate mimics and improves the carbamide
interaction of NAM and constitutes a new and improved
moiety for exploiting the C-site. Replacing the NAM
carboxamide with a hydroxamate moiety thus should improve
the affinity of this scaffold, but specificity should remain low
due to the conservation of the C-site. However, the Sirt6/TSA
complex shows that the distal compound part occupies a
binding region specific to Sirt6, explaining its isoform
selectivity.20 This region belongs to the Sirt6 acyl channel
exit, which is also exploited by pyrrolo[1,2-a]quinoxalines but
with different orientations and interacting patches (Figure
2F).14 We speculate that adding a related extension to the
existing TSA carbon branch at C6 would combine these
interactions in one molecule and could lead to superior affinity.
Another modification that might potentially increase potency
would be to change the methyl group at C4 to an amino group
to simulate the Pro62 interaction of the ring nitrogens of NAM
and UBCS activators (Figure 2F). The comparison with the
Sirt3/Ex527 complex (Figure 2B) also suggests that larger
moieties added to C3, such as a methylindole, might improve
sirtuin affinity, and they would also abrogate HDAC affinity
due to steric hindrance. This moiety would occupy the so-
called “extended C-site” (ECS) II, which is conserved among
sirtuins and thus will improve general sirtuin affinity as
discussed for the C-site.26,29 Linker and distal moiety, in
contrast, occupy the ECS III region, which differs between
isoforms and thus can contribute to isoform specificity.29,30
Generally, rigidifying the TSA linker and proximal group
conformation of the Sirt6 complex should allow abolishing of
effects on HDACs (see above). A possible strategy could be to
insert a double bond between C6 and C7, since the carbonyl
oxygen appears not to contribute significantly to Sirt6 binding.
Alternatively, several modifications to the TSA dimethylamino-
phenyl group can be envisioned for improving sirtuin binding
and specificity. The TSA phenyl plane is distorted against the
carbonyl oxygen and the carbonyl plane is bent, likely causing
an energetically less favorable conformation, to avoid clashes
with Trp71. Making the terminal group smaller could thus lead
to tighter binding. Also, making it less hydrophobic might
lessen its unfavorable solvent interactions through the
unbound surface and ridge, and it would weaken interactions
with the hydrophobic pocket it occupies in HDACs. Also,
shortening this group and adding an interaction partner for
other, isoform-specific residues, such as Sirt3-Arg158, could
allow exploiting of the TSA scaffold for the development of
compounds specific for sirtuin isoforms other than Sirt6.
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The strong HDAC inhibition by hydroxamates is mostly
based on their Zn chelate interaction, and methylation of the
hydroxamate hydroxyl group might retain the activity against
Sirt6 but prevent HDAC binding. The other way round,
improving HDAC inhibitors can be achieved by rigidifying the
ligand conformation observed in HDACs, for example, through
ring formation between the carbonyl and phenyl moieties in
SAHA. Also, extending the distal moiety with hydrophobic
groups might also increase HDAC over sirtuin specificity, since
it would further fill the corresponding HDAC binding site and
increase the steric hindrance in Sirt6.
In summary, we provide molecular insights in Sirt6 binding
mode and interaction details for TSA, the most potent small
molecule Sirt6 inhibitor reported so far. These insights provide
a rational basis for developing compounds that inhibit Sirt6,
other sirtuins, and HDACs with improved potency and/or
selectivity. Such compounds, in particular those targeting
sirtuins, are rare and urgently needed for functional studies and
as lead compounds for the development of therapeutic drugs.
Our data reveal the role of the hydroxamate as interactor for
the sirtuin C-site, identifying this moiety, or a modified version
abolishing binding to the HDAC active site Zn2+, as an
attractive group for sirtuin inhibitor development. They further
identify the relevance of chain modifications and conformation
for discrimination of Sirt6 versus other sirtuin isoforms and
Zn2+-dependent HDACs. These insights now allow for the
design of improved inhibitors.
■ EXPERIMENTAL SECTION
Chemicals. TSA was purchased from Invivogen. All other
chemicals were purchased from Sigma if not stated differently.
Protein Production and Purification. Human Sirt6 protein was
recombinantly produced and purified as described previously.14,31
Briefly, full-length Sirt6 (residues 1−355) in pQE80L.1 was expressed
in E. coli M15[pREP4] and Sirt6(13−308) in pET151-D-TOPO in E.
coli Rosetta2 (DE3) pLysS. Sirt6 protein was affinity purified using
Talon resin (Clontech) and the his-tag removed through tobacco etch
virus (TEV) protease cleavage and reverse affinity chromatography.
Sirt6 protein was then further purified through cation exchange
chromatography on SP Sepharose (GE Healthcare) and gel filtration
on a Superdex 200 column (GE Healthcare). The purified protein was
concentrated to 10 mg/mL, flash frozen in liquid nitrogen, and stored
at −80 °C.
Binding Assays. Binding of TSA to Sirt6 was analyzed through
label-free microscale thermophoresis measurements on a Monolith
NT.label-free (NanoTemper Technologies). Full-length Sirt6 at a
final concentration of 2 μM in 50 mM Na-phosphate buffer, pH 7.5,
0.6 mM DTT, and 5% DMSO was titrated with TSA stock solution
(12.1 mg/mL in DMSO). Prior to measurements, mixtures were
incubated for 20 min at room temperature. Thermophoresis was
analyzed at 25 °C with 20% laser power and 15% LED power. A
concentration-dependent fluorescence quenching was observed upon
binding, and the SDS-denaturation test indicated that the change of
the fluorescence signal was caused by the Sirt6/TSA interaction. Data
were fitted in GraFit7 with an equation for one binding site with
background. All experiments were repeated at least twice.
Crystallization and Structure Determination. Protein solution
containing 10 mg/mL Sirt6 (13−308) and 10 mM ADP-ribose was
mixed with an equal volume of reservoir solution (1.6 M (NH4)2SO4,
10% PEG 400, and Bis-Tris buffer, pH 5.7) and crystallized by the
hanging-drop vapor diffusion method at 20 °C. The Sirt6/ADP-
ribose/TSA was generated by soaking 10 mM TSA into Sirt6/ADP-
ribose crystals overnight. Crystals were transferred to a cryoprotectant
solution of reservoir supplemented with 20% ethylene glycol, 10 mM
compound, and 2 mM ADP-ribose before being frozen in liquid
nitrogen.
Diffraction data for the Sirt6/ADP-ribose/TSA complex were
collected at 100 K at BL14.1 at the BESSY II electron storage ring
operated by the Helmholtz-Zentrum Berlin (HZB), Germany.32 Data
were processed with “X-ray detector software” (XDS)33 and initial
phases determined by molecular replacement with Phaser34 from the
CCP4 software suite35 and a Sirt6/ADP-ribose structure (PDB code
3K35) as search model. The structure was rebuilt in COOT36 and
refined with Refmac.37 Since the crystal showed significant twinning
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Mammalian Sirtuin 6 (Sirt6) is an NAD+-dependent protein deacylase regulating metabolism 
and DNA homeostasis. Sirt6 activation protects against metabolic and aging-related diseases, 
and Sirt6 inhibition is considered for cancer therapy. Available Sirt6 modulators show 
insufficient potency and specificity, and partially contradictory effects were reported for the 
plant flavone quercetin and its derivatives. To understand Sirt6 modulation by this compound 
family and to support drug development, we analysed binding and activity effects of 
quercetin-based compounds on Sirt6 and other Sirtuin isoforms and solved crystal structures 
of compound complexes with Sirt6 and Sirt2. We find that quercetin activates Sirt6 via the 
isoform-specific binding site for pyrrolo[1,2-a]quinoxalines. Inhibition of other isoforms is 
based on an alternative binding site at the active site entrance. Based on these insights, we 
identified isoquercetin as a Sirt6 activator with increased specificity. Our results provide a 









Sirtuins are NAD+-dependent protein lysine deacylases that sense the cellular nutrient status, 
regulate energy metabolism and stress responses, and have been implicated in aging processes 
and aging-related diseases (Morris, 2013). Of the seven mammalian Sirtuin isoforms, Sirt1-7, 
three are localized in the nucleus (Sirt1,6,7). Sirt1 is the most studied isoform, functions as 
deacetylase of histones and transcription factors, and it is modulated by a variety of small 
molecule inhibitors and activators and used as a therapeutic target (Dai et al., 2018). Sirt6 
associates with chromatin and modulates the functions of histones, transcription factors, and 
stress response proteins to regulate gene expression, telomere maintenance, and DNA repair 
(Kugel and Mostoslavsky, 2014). Sirt6 promotes longevity in male mice, and it suppresses 
aging phenotypes and induces apoptosis in cancer cells (Kugel et al., 2016). Thus, small 
molecule Sirt6 modulators are sought for functional studies and therapy of aging-related 
diseases, such as cancer and type 2 diabetes (Tasselli et al., 2017).  
Sirtuins feature differing substrate acyl selectivities (Roessler et al., 2014, Gertz et al., 
2016, Pannek et al., 2017). Sirt6 hydrolyses lysine acylations by long chain fatty acids, such 
as myristoylations, more efficiently than acetylations in vitro, and TNF- demyristoylation 
regulates its secretion, but a broader relevance of this activity remains to be confirmed (Jiang 
et al., 2013). The same applies to Sirt6’s low mon-ADP-ribosylation activity, which can 
activate PARP1 to stimulate DNA repair (Mao et al., 2011). Despite its low in vitro 
deacetylase activity, Sirt6 efficiently deacetylates histones and proteins involved in glucose 
metabolism and DNA repair in vivo (Gil et al., 2013, Tasselli et al., 2017). It features the 
conserved Sirtuin catalytic core of ~275 amino acids, with a large Rossman-fold domain and a 
smaller Zn2+-binding domain, which shows larger variations among isoforms. The active site 
cleft between these domains comprises a substrate acyl-binding channel, and Sirt6’s particular 
small Zn2+-binding domain and cofactor-binding loop render it larger and more hydrophobic 
than in most other Sirtuins, enabling efficient accommodation of long-chain acyls. The Sirtuin 
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catalytic core is flanked by isoform-specific N- and C- terminal extensions, which in Sirt6 
contribute to chromatin localization  (Tennen et al., 2010).  
Only few Sirt6 modulators are available. Sirtuin-activating compounds (STACs) were 
initially described for Sirt1 (Dai et al., 2018). They bind to a Sirt1-specific STAC binding 
domain (SBD) (Dai et al., 2018), which might suggest that other Sirtuin isoforms are not 
amenable to activation. However, free fatty acids and fatty acid ethanolamides at high 
micromolar concentrations were found to stimulate Sirt6 deacetylation activity (Feldman et al., 
2013, Rahnasto-Rilla et al., 2016). They inhibit Sirt6-dependent hydrolysis of long chain 
acylations, implicating the acyl binding channel in this effect. Recently, we identified 
synthetic pyrrolo[1,2-a]quinoxaline derivatives as more potent Sirt6 deacetylase activators 
(Schlicker et al., 2011, You et al., 2017). Crystal structures of Sirt6/activator complexes 
identified a Sirt6-specific modulator binding site in the acyl binding channel and provided a 
rational basis for further development (You et al., 2017), which will be necessary for in vivo 
applications due to their limited efficacy and solubility. Another low potency Sirt6 activator 
appears to be the flavonoid quercetin (Fig. 1A), which is present in fruits and vegetables and 
has anti-inflammatory and anti-diabetic effects (Williams RJ et al., 2004, Russo GL et al., 
2014). Quercetin was among the Sirt1 activating polyphenols identified with the fluorogenic 
“Fluor-de-Lys” (FdL) substrate (Howitz et al., 2003) and was reported to inhibit Sirt6 in the 
same assay (Kokkonen et al., 2014). Later, quercetin was reported to act as a Sirt6 inhibitor at 
low and a Sirt6 activator at high concentrations based on mass spectrometry (MS) assays 
(Rahnasto-Rilla et al., 2016), but a recent MS study by the same group yielded only Sirt6 
activating effects for quercetin and an improved derivative (Rahnasto-Rilla et al., 2018). It 
further indicated the quercetin derivatives catechin gallate and gallocatechin gallate as first 
potent Sirt6 inhibitors (IC50 2.5 and 5.4 µM, respectively; Fig. 1A). Although quercetin and its 
derivatives affect several cellular targets (Russo GL et al., 2014), their Sirtuin binding site and 
modulation mechanism would be highly helpful for the development of potent and soluble 
5 
Sirt6 modulators. A pharmacophore model (Ravichandran et al., 2014) and docking 
calculations (Rahnasto-Rilla et al., 2018) failed to rationalize the limited and partially 
contradictory experimental data on Sirt6 modulation, hindering their use for drug 
development.  
Here, we analyse modulation of Sirt6 and other isoforms by quercetin and its 
derivatives in activity and binding assays and through crystal structure analysis of modulator 
complexes of Sirt6 and Sirt2. We find that quercetin-based compounds can activate or inhibit 
Sirt6-dependent deacetylation through binding to the Sirt6-specific acyl binding channel. 
Quercetin inhibits other Sirtuin isoforms through binding at the active site entrance, and 
isoquercetin can distinguish the binding sites and thus activates Sirt6 selectively. Our results 
hence provide structural insights in Sirtuin modulation by quercetin-based compounds and a 





Quercetin and its derivative luteolin activate Sirt6-dependent deacetylation 
To clarify the effects of quercetin and its derivatives on Sirt6 deacetylation activity, we tested 
them in several assays. In the FdL assay, quercetin appeared to inhibit Sirt6 but control 
reactions showed that it quenches FdL fluorescence, preventing reliable measurements 
(Supplementary Fig. 1A). In a coupled enzymatic assay with acetylated H3K9 peptide 
(H3K9Ac), which represents a physiological Sirt6 deacetylation site, quercetin also appeared 
to inhibit Sirt6 but control reactions revealed suppressive effects on the assay’s downstream 
enzymes (Supplementary Fig. 1B). To overcome the artifacts in these widely used assays, 
we tested the compounds by using a robust MS-based assay (Fischer et al., 2012) and the 
H3K9Ac substrate. Quercetin and luteolin tested from 9.8 µM to 10 mM revealed a dose-
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dependent increase in Sirt6 activity, with a maximum stimulation of more than 2-fold and 
EC50 values of ~1.2 mM (Fig. 1B). We did not observe any evidence for Sirt6 inhibition by 
these compounds.  
 Acetyl-peptides are poor substrates for Sirt6 and may not fully mimic physiologic 
conditions of histone deacetylation in cells (Michishita et al., 2008, Gil et al., 2013). We 
therefore examined the effects of quercetin on the deacetylation activity of Sirt6 on purified 
nucleosomes and free full-length histones (Fig. 1C). We observed substantial activation of 
Sirt6 by quercetin in deacetylating nucleosomal H3K18ac (H3K9ac levels were below the 
detection limit on these nucleosomes). Moreover, quercetin also augmented the H3K18ac and 
H3K9ac deacetylase activities of Sirt6 on free full-length histones (Fig. 1C), which are 
otherwise poor substrates for Sirt6. These findings demonstrate that quercetin has activating 
effects on Sirt6-dependent deacetylation of its physiological histone substrates. 
 
A Sirt6/quercetin crystal structure reveals binding site and interaction details 
To identify Sirt6’s quercetin binding site and interaction details, we determined a crystal 
structure of a Sirt6/ADP-ribose/quercetin complex. The structure was solved at 1.84 Å 
resolution (Table 1) and contained well-defined electron density for one quercetin ligand per 
Sirt6 monomer (Fig. 1D,E). The binding site is located in the hydrophobic funnel that 
comprises the distal end of Sirt6’s extended acyl binding channel (Fig 1D,E). Quercetin’s 
catechol moiety (ring B) is buried in a protein pocket and its 4’-hydroxyl group forms a 
hydrogen bond to the Pro62 backbone oxygen, and the 4’- and 3’-hydroxyls form water-
mediated interactions with the backbone of Ala53 and Ile61 and the side chain of Asp116 (Fig. 
1E,F). Asp116 also forms a hydrogen bond to the NAM moiety of the cosubstrate NAD+ in 
its binding site known as “C-site”, illustrating that catechol pocket and C-site are partly 
overlapping (see also below). The quercetin chromen-4-one system forms no polar 
interactions but contributes to complex formation through hydrophobic contacts with funnel 
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surface patches formed by Phe64/82/86 and Val70/115, and Met136/157 (Fig. 1F). 
Comparison of the Sirt6/quercetin complex with a Sirt6 complex with the pyrrolo[1,2-
a]quinoxaline-based activator UBCS039 shows that they share most of their binding sites (Fig. 
1F). Quercetin’s catechol group overlays well with the UBCS039 pyridine moiety and 
reproduces its key interaction to Pro62 (You et al., 2017). The chromen-4-one substitutes for 
the hydrophobic pyrrolo[1,2-a]quinoxaline of UBCS039-related compounds, which varies 
between UBCS039 derivatives due to the non-directed nature of its interactions and the wide 
and hydrophobic architecture of the Sirt6 funnel (You et al., 2017). It thus appears that the 
buried catechol group of quercetin functions as an anchor in Sirt6 binding, while the chromen-
4-one provides smaller and non-specific binding contributions. The chromen-4-one thus 
appears particular attractive for modifications to improve compound binding and potency.  
Since quercetin occupies the distal end of the extended Sirt6 acyl channel it is 
compatible with binding of acetylated substrates but would overlap with longer substrate 
acylations such as myristoylations (Supplementary Fig. 1C). Consistently, testing quercetin 
on Sirt6-dependent demyristoylation revealed a concentration-dependent inhibition (Fig. 1G). 
Thus, quercetin activates Sirt6’s deacetylation activity and inhibits Sirt6-dependent 
demyristoylations, as observed for UBCS039 and consistent with their binding to the remote 
end of the Sirt6 acyl channel. 
 
Sirt6 complex structures with inhibitory and activating quercetin derivatives reveal 
interaction differences and suggest modulation mechanisms 
Catechin gallate (CG) was reported to be the most potent compound among quercetin 
derivatives that inhibit Sirt6-dependent deacetylation (Rahnasto-Rilla et al., 2018). Testing 
CG in our MS assay confirmed the inhibition, albeit with lower potency (IC50 80 ± 15 M; 
Fig 2A) than reported (IC50 2.5 ± 0.1 M). To rationalize the inhibitory effect, we determined 
a crystal structure of a Sirt6/CG complex. The structure was solved at 2.0 Å resolution and 
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comprised well-defined electron density for one CG ligand per Sirt6 monomer (Table 1;.Fig. 
2B). CG occupied the same binding region as quercetin (Fig. 2C,D), with identical positions 
for their catechol moieties but with a rotated chromen-4-one orientation in GC to 
accommodate its additional, bulky trihydroxy benzoyl group (Fig. 2E). The chromen-4-one 
now interacts with Trp71 of the acyl channel exit, and the trihydroxy benzoyl group forms 
hydrophobic interactions with the other side of the exit funnel and a polar contact to the 
backbone nitrogen of Gly155. The inhibitor does not overlap with the binding pocket for 
acetyl substrate but catechol group assumes a position perpendicular to, and partly 
overlapping with the NAM moiety of the NAD+ cosubstrate (Supplementary Fig. 2A). The 
inhibition could thus be based on NAD+ competition, but the fact that closely related 
compounds with identical catechol binding mode act as activators suggests that binding 
occurs only after NAM release from NAD+ during catalysis (see discussion). 
Cyanidin is an quercetin derivative that was reported to activate Sirt6 with increased 
potency and efficacy (EC50 460 ± 20 µM; 55-fold stimulation) (Rahnasto-Rilla et al., 2018). 
In our activity assays, cyanidin showed some Sirt6 activation at lower concentrations (20-80 
M) but caused heavy precipitation at higher concentrations, preventing reliable 
measurements (Fig. 2F). Our data indicate indeed a higher potency than for quercetin, albeit 
lower than reported, and they do not allow conclusions on the efficacy. To obtain insights in 
activation mechanism and compound optimization options, we solved a crystal structure of a 
Sirt6/ADP-ribose/cyanidin complex (Table 1; Fig. 2G). The activator is well-defined by 
electron density for its B-ring catechol, but features weaker density for the A and C ring 
system, which could have functional relevance but might also be caused by the lower 
solubility (and resulting occupancy) of cyanidin. The A/C rings nevertheless can be 
positioned unequivocally in the same acyl exit funnel region as for quercetin (Fig 2H), and 
the compounds thus show the same binding mode.  
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The keto group at C-ring position 4 of quercetin that is missing in cyanidin and also in 
the potent inhibitor CG removes an unfavourable interaction with Met157 and might be a key 
difference causing their increased potency. Comparing the activating and inhibiting 
compounds and their Sirt6 complexes further suggests modulation mechanisms and relevant 
differences causing their differing effects. An overlay of the complex structures shows that 
the inhibitor CG differs from activators in a slight rotation of the catechol moiety and a bulky 
substituent extended toward the N-terminus, but the observed differences in protein 
conformation are subtle. Both compound types, however, overlap with the C-site that 
accommodates the NAM moiety of the substrate NAD+ until NAM is released in the first 
catalytic step. Such a binding mode for activators implies that they bind during or after NAM 
release. Such a scheme was thoroughly characterized for the Sirtuin inhibitor Ex-527 (Gertz et 
al., 2013), and we speculate that the quercetin-based activators and inhibitors, which are very 
similar to each other, share this mechanistic feature. Different effects on the stabilization of 
the acyl channel conformation of Sirt6/product complexes, possibly due to the chromene 
group pointing toward the N-terminus, might cause their differing effects on Sirt6 deacetylase 
activity, but details remain to be established. 
 
Quercetin inhibits other Sirtuin isoforms by exploiting an alternative binding site 
Due to the isoform-specific features of the Sirt6 acyl channel, in particular its wide and 
hydrophobic architecture (Supplementary Fig. 2B), its ligands should be Sirt6 specific. 
However, effects of quercetin and related polyphenols were also reported for Sirt1 (Howitz et 
al., 2003)– Format not correct, no initials are given for other references!. We thus tested the 
quercetin isoform specificity in activity assays with human Sirt1, Sirt2, Sirt3, Sirt6 (all with 
acetylated substrate), and Sirt5 (with succinylated substrate). Quercetin caused a 
concentration-dependent inhibition of all Sirtuin isoforms except for Sirt6, with more than 80% 
activity reduction at 1250 µM (Fig. 3A). Due to the lack of a Sirt6-like binding site, quercetin 
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has to exploit an alternative binding site of the other isoforms to cause this opposite, 
inhibitory effect.  
To identify the alternative quercetin binding site and modulation mechanism, we 
determined a crystal structure of a Sirt2/quercetin complex. The structure was solved at 2.2 Å 
resolution and revealed well-defined electron density for one quercetin molecule per Sirt2 
monomer (Table 1; Fig. 3B,C). Quercetin binds on the protein surface at the active site 
entrance, through π-π stacking with Tyr-114 and Phe-235 and anion–π interaction with Glu-
116 and Glu-120 (Fig. 3C,D). Interestingly, the bound quercetin locates between two 
symmetry-related Sirt2 monomers and interacts with the same surface region of the second 
monomer, albeit through fewer contacts and with rotated orientation (Supplementary Fig. 
2C). An overlay with a Sirt2/substrate peptide complex reveals that quercetin partly occupies 
the pocket accommodating substrate residues C-terminal from the acetyl-Lys (respective the 
C-terminal fluorophore in FdL substrate) and thus sterically prevents substrate binding (Fig. 
3E). Such a peptide competitive mechanism is supported by Sirt2 inhibition tests at different 
substrate concentrations, which showed that increasing substrate concentrations lead to 
weaker inhibitory effects of a fixed inhibitor concentration (Fig. 3F).  
Comparing the Sirt2/quercetin complex to other Sirtuin isoforms reveals that its 
binding site is also accessible in Sirt1, 3, and 5, whereas it is occupied in Sirt6 by the protein’s 
N-terminus (Fig. 3G). Since Sirt6’s quercetin binding site is blocked in these other isoforms 
by cofactor loop and a helix bundle (Supplementary Fig. 2D), our structures define two 
mutually exclusive modulator binding sites for Sirt6 and for Sirt1,2,3,5, respectively.  
  
Isoquercetin is an activating ligand for the quercetin site with improved specificity 
Since the quercetin sites of Sirt6 and Sirt1,2,3,5 are mutually exclusive, suitable derivatives 
should exploit specific features of either side and thus show improved selectivity. We thus 
tested the isoform selectivity of the quercetin derivative isoquercetin, which features a bulky 
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sugar moiety that might be accommodated in one binding site but not the other. Indeed, 
isoquercetin retained the Sirt6 stimulating activity, albeit with even lower potency, but it 
showed no significant effects on Sirt1-3-dependent deacetylation and Sirt5-dependent 
desuccinylation (Fig. 3G). To clarify the molecular basis of isoquercetin’s improved Sirt6 
selectivity, we tried to determine a crystal structure of a Sirt6/ADP-ribose/isoquercetin 
complex. Initial soaking experiments failed, however, and we speculated that a PEG molecule 
bound to the acyl site and potentially overlapping with the isoquercetin sugar prevents binding. 
Substituting PEG with ethylene glycol indeed enabled us to solve the Sirt6/isoquercetin 
complex structure at 1.8 Å resolution (Table 1; Fig. 3H). The quercetin moiety of 
isoquercetin occupies the activator site identical to the parent compound (Fig. 3H,I). The 
additional sugar moiety of isoquercetin is thereby placed in the acyl channel and would 
indeed overlap with the PEG molecule of the quercetin complex. The density for the 
isoquerectin sugar is weaker than for its quercetin moiety, likely due to flexibility, and it 
indeed forms no significant positive interactions (Fig. 3H,I). Placing isoquercetin instead on 
top of the ligand of our Sirt2/quercetin structure reveals that the sugar moity would clash with 
Tyr-114, rationalizing the improved selectivity for Sirt6 (Fig. 3J). The sugar thus acts as a 
negative selector, i.e. does not disturb Sirt6 binding significantly but hinders accommodation 
in the alternative binding site of the other isoforms, indicating this position as an attractive 
site for improvement of the compounds selectivity and – with more appropriate moieties for 
beneficial interactions – of its potency.  
 
Discussion 
Sirt6 supports longevity and suppresses aging phenotypes, and it is considered an attractive 
drug target for aging-related diseases (Morris, 2013, Howitz et al., 2003, Kugel et al., 2016). 
For pharmacological applications, the few available Sirt6 modulators require improvements 
concerning potency, selectivity, and bioavailability (You et al., 2018, Dai et al., 2018). They 
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comprise quercetin and some of its derivatives, a family of plant flavones with beneficial 
health impact, for example through anti-inflammatory and anti-diabetic effects (Williams et 
al., 2004, Russo et al., 2014). Partly contradictory effects were reported for quercetin effects 
on Sirt6 activity (Kokkonen et al., 2014, Rahnasto-Rilla et al., 2016, Ravichandran et al., 
2014), and we find that the compound interferes with two popular Sirtuin activity assays, 
which is a common problem for optical assays (Fischer et al., 2012). Our tests in a robust MS 
assay confirm, however, that quercetin and luteolin act as low potency activators for Sirt6-
dependent deacetylation. Previously reported inhibitory quercetin effects at lower 
concentrations could not be observed and likely are assay artifacts, possibly due to the 
compounds’ optical effects or the use of Sirt6 tagged with GST, which is known to bind 
quercetin tightly (Ahmad et al., 2017). Excitingly, more potent quercetin-based Sirt6 
activators such as cyanidin were reported recently (Rahnasto-Rilla et al., 2018), indicating 
that potency and specificity of this scaffold can be improved for pharmacological applications 
and that Sirt6 modulation might contribute to physiological effects of compound family 
members. Despite some discrepancies in EC50 and efficacy values (Supplementary Table 1), 
which might be due to competition with NAD+ or NAM or an influence of the previously 
used GST-tag, our MS data confirm the activating effect and improved potency compared to 
quercetin. Quercetin itself affects a variety of other cellular targets, such as kinases, with 
much higher potency than Sirt6 (IC50 values in the 0.1-15 M range (Kokkonen et al., 2014)), 
which thus appears not to be a direct target mediating the compound’s beneficial health 
effects. It might contribute indirectly, though, for example through its activation by increased 
NAD+ levels from quercetin inhibition of CD38 (Kellenberger et al., 2011). However, Sirt6 
might be a relevant direct target for physiological effects of the identified, more potent 
quercetin-based compounds and/or for yet to be identified, even more potent derivatives or 
metabolites. Due to the wide Sirt6 binding side and the few specific interactions, it can even 
be envisioned that other natural compound families with a catechol group or a related moiety 
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for binding in this pocket can exploit this binding mode, possibly with even higher affinity 
and physiological relevance. They could be the explanation why the deacetylase activity of 
Sirt6 is weak in vitro yet robust and significant in vivo (Tasselli et al., 2017), and it woul thus 
be exciting if such compounds could be identified. Interestingly, some quercetin derivatives 
show an inhibitory rather than activating effect on Sirt6. We could confirm this finding and 
the increased potency, albeit of differences in IC50 values (Supplementary Table 1) possibly 
caused by the previously used GST-tag (Rahnasto-Rilla et al., 2018). Our assays further 
establish that quercetin inhibits other human Sirtuin isoforms with low potency, but more 
potent quercetin derivatives might also exist for these isoforms. Inhibition of Sirt6 and 
possibly also of other Sirtuin isoforms thus might also contribute to physiological effects of 
flavones or flavone-containing food or extracts. 
For understanding the effects of quercetin-based compounds on Sirtuins and for 
exploiting them for drug development, details of the Sirtuin/compound interactions are 
required. A pharmacophore model for Sirt6-binding of quercetin derivatives was based on 
binding competition among these ligands and suggested four relevant hydrogen bonds 
(Ravichandran et al., 2014). Docking models for Sirt6-modulating quercetin derivatives 
suggested binding in the active site and acyl channel region, with partly peptide-competitive 
interactions for inhibitors and more external binding for activators (Rahnasto-Rilla et al., 
2018). Both models were based on experimental data that were limited – binding of few 
compounds, without information on effects on activity respective activity effects of few 
derivatives – and partially incorrect (see discussion of dual effects on Sirt6 activity above). 
Our complex crystal structures in fact identify a deviating Sirt6 binding mode and provide 
detailed insights in interactions and modulation mechanisms. The complexes identify 
quercetin’s catechol moiety as a key interaction moiety, which binds to the bottom of the 
Sirt6-specific acyl channel similar to the pyridine ring of activating pyrrolo[1,2-
a]quinoxalines (You et al., 2017), leading to an overlap with the C-site that accommodates the 
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NAM moiety of NAD+. The larger chromene moiety, in contrast, contributes mostly non-
directional hydrophobic contacts and thus can assume different orientations within the Sirt6 
acyl exit funnel, depending on its substituents. This compound part thus appears most 
attractive for modifications to improve the interaction by introducing groups for polar 
interactions. Chromene substituents also seem dominant in determining whether a ligand 
activates or inhibits, but the details of this mechanistic difference remain to be clarified. 
However, the comparison with the pyrrolo[1,2-a]quinoxalines show that the more soluble 
quercetin moieties can substitute for rather hydrophobic moieties without significant loss of 
potency, which can be exploited in chimeric compounds or stimulate the development of 
other polar ligand moieties. Importantly, the general binding mode is identical for activators 
and inhibitors, and they would thus both overlap with the NAM moiety of NAD+. Rather than 
proposing competitive inhibition, which would leave the activating effects unexplained and 
require a different interaction scheme among ligands, we assume that the compounds bind 
only after NAM release from NAD+ within the first catalytic step (Fischer et al., 2012). Such 
a binding mode has already been established for the Sirtuin inhibitor Ex-527 (Gertz et al., 
2013) and was also indicated for the inhibition of Sirt6 by trichostatine A (You et al., 2018). 
The distinct presence and orientation of chromene substituents of quercetin derivatives seem 
to contribute to the different potencies and effects (inhibition versus activation), and likely 
also interaction details yet to be identified from larger SAR studies and their analysis based on 
our complex structures. There might also be quercetin derivatives that occupy this site without 
a significant effect on Sirt6 deacetylase activity, as observed for the pyrrolo[1,2-a]quinoxaline 
UBCS059 (You et al., 2017). Due to the competition of these compounds with myristoylated 
substrate, but not with acetylated polypeptides, they constitute another interesting family of 
modulators specifically inhibiting the demyristoylation activity of Sirt6 without effects on its 
deacetylation activity. 
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Our structures readily explain the Sirt6-specific activation effects, the weak inhibition 
against other isoforms, and how derivatives can have isoform specific effects. Quercetin can 
occupy two largely different binding sites in Sirt6 versus all other isoforms. Our assay and 
structural data on isoquercetin show that this derivative extends with its additional sugar 
moiety into the acyl channel, whereas it would lead to a clash in the binding sites of 
Sirt1,2,3,5. This finding suggests modifications on the quercetin C ring as possibility to 
increase Sirt6 affinity as well as selectivity. In principle, our structures also provide 
information for improving the inhibitory binding to other Sirtuin isoforms, but strong and 
isoform-specific binding might be difficult to achieve due to their related and rather flat and 
exposed sites. Thus, our complex structures primarily provide vast information for further 
development of Sirt6 activators and inhibitors, based on the quercetin scaffold but also for 
development based on chimeras with other known ligands or novel, to be identified scaffolds 
that can occupy this binding region.  
 
Significance  
Quercetin is a plant flavone with beneficial health effects. It affects many targets and shows 
weak effects on Sirt6, an NAD+-dependent deacylase that supports longevity and suppresses 
aging phenotypes. Sirt6-targeting drugs, in particular activators, are considered attractive for 
therapy of aging-related diseases. Contradictory quercetin effects on Sirt6 deacetylase activity 
have been reported, and we could clarify that inhibitory effects are assay artifacts and that the 
compound acts as Sirt6 activator. Importantly, more potent Sirt6-activating quercetin 
derivatives were recently identified and confirmed in our study, and also potently Sirt6-
inhibiting derivatives. Sirt6 modulation thus might contribute to physiological effects of such 
flavones, and the quercetin scaffold and insights in its Sirt6 binding mode can provide a basis 
for the development of pharmacological modulators. We therefore solved and analysed crystal 
structures of Sirt6 complexes with quercetin and activating as well as inhibiting derivatives to 
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identify their binding site and interaction details. Quercetin binds to with its chromene group 
to the Sirt6 acyl channel exit and with its catechol group in a deep target pocket. All quercetin 
derivatives bind with identical catechol group positions, while the chromene orientation can 
slightly vary depending on substituents. The compounds further bind similar to previously 
described pyrrolo[1,2-a]quinoxaline-based activators that suffer from low solubility and 
efficacy. Our data suggest a mechanism for Sirt6 modulation and factors that render a 
compound activating or inhibitory, and they provide a scaffold with improved solubility and 
details for derivative design for further development of Sirt6 deacetylase activators and 
inhibitors. They also support development of compounds that solely inhibit Sirt6’s alternative 
demyristoylation activity. Quercetin-based compounds further showed weak inhibition of 
other Sirtuin isoforms, and solving a Sirt2/quercetin complex structure revealed an alternative 
binding site in Sirt1,2,3,5 but covered in Sirt6 by its N-terminus. This site is rather exposed 
and less promising for drug development, but rationalized the improved Sirt6 specificity of 
isoquercetin, illustrating that is can support Sirt6 drug development. Our findings further 
indicate how additional natural compounds might exploit this Sirt6 binding site, suggesting 
that a cytosolic ligand for this site might be responsible for the discrepancy between Sirt6’s 
low in vitro and robust in vitro deacetylase activity.  
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Materials and Methods 
 
Chemicals 
All chemicals were purchased from Sigma (Saint Louis, USA) if not stated differently. All 
other synthetic peptides were from GL Biochem (Shanghai, China; myristoyl-TNF: EALPK-
(myristoyl-K)-TGG); acetyl-H3K9: MARTKQTAR-(acetyl-K)-STGGKAPRKQL; acetyl-p53: 
RHK-(acetyl-K)-LMFK; acetyl-a-tubulin: MPSD-(acetyl-K)-TIG; acetyl-ACS2: TRSG-
(acetyl-K)-VMR; succinyl-CPS1: RGVL-(succinyl-K)-EYGV). 
 
Protein production and purification 
The recombinant N-terminal his-tagged human Sirt6 proteins were produced as previously 
described (Schlicker et al., 2011). Briefly, Sirt6(1-355) in pQE80L.1 was fermented in E. coli 
M15[pREP4]; Sirt6(13-308) in pET151-D-TOPO was expressed in E. coli Rosetta2 (DE3) 
pLysS. Human Sirt2(55-356) was expressed from a pET-SUMO vector in E. coli BL21 (DE3) 
codon+. The proteins were purified by affinity chromatography with Talon resin (Clontech), 
followed by tag cleavage with Tobacco Etch Virus (TEV) protease. Tag and protease were 
removed through a second Talon affinity chromatography, and the proteins were further 
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purified using cation exchange and gel filtration chromatography. Purified protein was 
concentrated to 10 mg/ml for Sirt6 and 36.5 mg/ml for Sirt2, flash frozen in liquid nitrogen, 
and stored at -80 °C. 
 
Peptide deacylation assays 
For coupled enzymatic peptide deacylation assays, reactions were run in a total volume of 100 
µl containing 50 mM Na-phosphate pH 7.50, 5% DMSO, 0.6 mM DTT, 0.1% (v/v) Tween 20, 
200 µM acetylated histone H3K9 peptide, 500 µM NAD+ and 10 µM Sirt6. The reactions 
were monitored in an Epoch 2 plate reader (BioTek) at 340 nm wavelengths. Control 
reactions to check for compound effects on downstream enzymes contained no Sirt6 and were 
spiked with 40 µM nicotinamide.  
For FdL assays, reactions were run in a total volume of 50 µl containing 50 mM Tris-
HCl pH 7.50, 100 mM NaCl, 5% DMSO, 100 µM acetylated FdL1-peptide, 500 µM NAD+ 
and 10 µM Sirt6. After incubation at 37 °C for 1h, reactions were stopped by adding 2 mM 
NAM and 10 mg/ml trypsin, incubated 20 min, and measured in a FluoDia T70 (Photon 
Technology) at wavelengths 460 nM. Control reactions for fluorescence quenching effects of 
the compounds were run by adding compound at different concentrations after the 
deacetylation and development steps.  
For MS deacetylation assays, reactions contained 50 mM Na-phosphate pH 7.5, 200 
µM H3K9ac peptide, 2.5 mM NAD+, 5% DMSO, the indicated amount of compound and 20 
µM Sirt6(1-355). Demyristoylation assays were done with 50µM myristoyl-TNFα peptide. 
Reference reactions contained 5% DMSO and no compound, and control reactions were run 
without Sirt6. After incubation for 2 h at 37 °C, reactions were stopped by adding equal 
volumes of 0.5% (v/v) trifluoroacetic acid and diluted 10-fold with 0.1% formic acid. 
Samples were filtered in 10 kDa MWCO concentrators and analyzed on an LTQ-XL mass 
spectrometer (Thermo Scientific) coupled to an HPLC-system with a self-packed ReproSil-
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Pur C18-AQ column. Demyristoylation samples were analyzed on a TripleTOF 5600+ 
System (SCIEX) coupled to an HPLC-system with a Jupiter 5u C4 300A column 
(Phenomenex) without prior filtration.  Peptide quantification was done with Skyline 
(Maclean et al., 2010). For the Sirt1, 2, 3, and 5 deacylation assays, the reaction mixtures 
contained 100 µM acetyl-p53 (Sirt1), 100 µM acetyl-α-tubulin (Sirt2), 100 µM acetyl-ACS2 
(Sirt3), or 100 µM succinyl-CPS1 (Sirt5), respectively. Sirt3 samples contained in addition 
0.05 mg/ml nicotinamidase. All reactions further contained 500 µM NAD+ and indicated 
amounts of compounds in 50 mM Na-phosphate buffer with 5% DMSO and were incubated 
for 5 min at 37 °C. MS analyses of the peptides were done as described for Sirt6 
 
In vitro histone and nucleosome deacetylation assays 
2 μg GST or GST-Sirt6 protein was pre-incubated with 5 mM quercetin or DMSO vehicle at 
room temperature for 10 minutes. In vitro deacetylation reactions were then performed by 
adding 5 μg calf thymus histones or 2 μg HeLa mononucleosomes (Epicypher) in 
NAD+ deacetylation buffer (20 mM Tris pH 8, 150 mM NaCl, 1 mM NAD+, 1.5 mM DTT), 
incubated at 30 °C for 3 hours in a total volume of 20 μl. Histone deacetylation was assessed 
by western blot with H3K9ac (ab4441) or H3K18ac (ab1191) specific antibodies. Signals 
were quantified with Image Studio™ Lite software (LI-COR Biosciences), and relative 
acetylation determined by normalization to total H3 and control samples. 
 
Crystallization and Structure determination 
Sirt6/ADP-ribose crystals were grown from 1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris 
buffer pH 5.7 with 10 mg/ml Sirt6(13-308) and 10 mM ADP-ribose by the hanging drop 
vapor diffusion method at 20 °C (You et al., 2017). The Sirt6/ADPr/quercetin and Sirt6/ADP-
ribose/cyanidin complexes were obtained by soaking Sirt6/ADP-ribose crystals with 40 mM 
compound for one week, and the Sirt6/ADP-ribose/CG complex by soaking with 1 mM CG 
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overnight. The structure in complex with isoquercetin was produced by transferring crystals in 
a new drop containing 1.6 M (NH4)2SO4, 10% ethylene glycol, and Bis-Tris buffer pH 5.7 
with 40 mM isoquercetin and incubation for one week. A solution of reservoir supplemented 
with 20% ethylene glycol, 10 mM compound and 2 mM ADP-ribose was used as 
cryoprotectant. 
Sirt2/ADP-ribose crystals were grown in hanging drops at 20 °C with 14 % PEG 
10.000 and 0.1 M ammonium acetate pH 5.8 as reservoir solution (Rumpf et al., 2015). The 
protein solution contained 13 mg/ml Sirt2 (55-356) and 20 mM ADP-ribose. The Sirt2/ADP-
ribose crystals were soaked with 40 mM quercetin for 3 days. Crystals were then transferred 
to a drop of reservoir supplemented with 20% glycol, 10 mM quercetin and 2 mM ADP-
ribose before flash freezing in liquid nitrogen. 
Diffraction data were collected at 100 K at BL14.1 operated by Helmholtz-Zentrum 
Berlin (HZB) at the BESSY II electron storage ring (Berlin-Adlershof, Germany) {Mueller, 
2012}. Diffraction data were processed with the X-ray Detector Software (XDS) using 
XDSapp (Kabsch, 2010a, Kabsch, 2010b). Structure were solved by “molecular replacement” 
phasing with Phaser (McCoy et al., 2007) from the CCP4 software suite (Winn et al., 2011), 
using the Sirt6/ADP-ribose structure (PDB code 3K35) as a search model for the Sirt6 
complexes and Sirt2/1,2,4-Oxadiazole/ADP-ribose structure (PDB code 5MAR) for the Sirt2 
complex. The structures were manually rebuilt in COOT (Emsley and Cowtan, 2004) and 
refined with Refmac (Murshudov GN et al., 1997). The Sirt6 crystals were detected to be 
twinned (twin fractions 28 % for Sirt6/isoquercetin/ADP-ribose, 44 % for Sirt6/CG/ADP-
ribose, 26 % for Sirt6/cyanidin/ADP-ribose, and 22 % for Sirt2/quercetin/ADP-ribose) and 
refinements were performed with amplitude-based twin refinement.  
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Table 1 Diffraction data and refinement statistics 








Data collection      
Space group                        P63 P63 P63 P63 P212121 
Cell dimensions      
    a= b, c (Å) 91.4, 143.9 91.4, 144.2 91.8, 144.2 91.4, 143.8 78.2, 114.5 











 a 0.12 (1.76) 0.10 (1.63) 0.16 (1.90) 0.16 (1.84) 0.28 (1.90) 
CC1/2










I / I a 11.6 (1.1) 13.2 (1.2) 9.7 (1.3) 11.0 (1.3) 4.4 (0.7) 
Completeness (%)a 99.7 (98.5) 99.9 (99.3) 98.9 (96.2) 99.9 (99.5) 99.5 (97.1) 
Redundancy a 6.9 (6.9) 6.9 (6.6) 10.1 (8.5) 11.3 (11.3) 7.4 (7.4) 
      
Refinement      










No. reflections 56832 51587 42989 37769 32823 
Twin fractionsb none 0.72/0.28 0.56/0.44 0.74/0.26 0.78/0.22 
Rwork / Rfree (%) 16.8/20.3 15.3/18.7 16.3/19.3 16.3/20.0 21.1/23.0 
No. atoms      
    Protein 4382 4381 4350 4341 4735 
    Compound 44 66 64 42 22 
    ADP ribose 72 72 72 72 72 
    Water 346 224 166 117 28 
B-factors      
    Protein 38.9 46.7 41.9 54.0 53.9 
    Compound 59.3 77.9 51.2 80.1 67.3 
    ADP ribose 28.7 36.1 30.2 41.8 34.8 
    Water 43.9 46.2 38.0 48.5 46.4 
R.m.s. deviations      
    Bond lengths (Å) 0.013 0.014 0.015 0.012 0.014 
    Bond angles () 1.84 2.11 2.26 1.95 2.2 
      
aHighest-resolution shell is shown in parentheses.  
bTwo twin domains were found in structure determination; twin fractions were estimated by 






Figure 1: Activation of Sirt6-dependent deacetylation and crystal structure of a 
Sirt6/quercetin complex. (A) Chemical structures of quercetin and its derivatives. (B) Dose-
dependent effects of quercetin and luteolin on Sirt6 deacetylation activity. (C) Western blots 
showing deacetylation activity of SIRT6 on purified Hela cell nucleosomes (left) or free 
histones (right), and activation by quercetin (5mM) compared to DMSO vehicle control. Data 
are representative of 3 independent experiments. Relative acetylation on the indicated sites 
was determined by normalization to total H3 and control samples. (D) Overall structure of the 
complex between human Sirt6 (cartoon), ADP-ribose (yellow sticks), and quercetin (cyan 
sticks); His133 is shown as sticks to indicate the active site. (E) Interaction of quercetin with 
Sirt6. Interacting residues are labeled, and polar interactions are indicated by dashed red lines. 
2Fo-Fc electron density for the ligand is contoured at 1σ. (F) Protein surface of the 
Sirt6/quercetin complex colored according to the electrostatic potential. The ligand is shown 
as cyan sticks and overlayed with UBCS039 (orange sticks). (G) Titration with quercetin 
inhibits Sirt6-dependent demyristoylation. Data are shown as means ± SD (n = 3).  
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Figure 2: Effects of quercetin derivatives on Sirt6 and crystal structures of 
Sirt6/quercetin derivative complexes. (A) Dose-dependent effects of CG on Sirt6 
deacetylation activity. (B) Interaction of CG with Sirt6. Interacting residues are labeled, and 
polar interactions are indicated by dashed lines. CG is covered with 2Fo-Fc density contoured 
at 1σ. (C) Schematic view of the Sirt6/CG interactions. (D) Overlay of Sirt6 complexes with 
CG (cyan) and quercetin (gray), respectively. ADP-ribose (yellow) and His133 at the active 
site are shown as sticks. (E) Dose-dependent effects of cyanidin on Sirt6 deacetylation 
activity, red symbols indicate solubility problems at high concentrations. (F) Interaction of 
cyanidin with Sirt6. Interacting residues are labeled, and polar interactions are indicated by 
dashed lines. 2Fo-Fc electron density for the ligand is contoured at 1σ. (G) Protein surface of 
the Sirt6/cyanidin complex colored according to the electrostatic potential. The ligand is 
shown as cyan sticks and overlayed with quercetin (gray sticks). 
28 
 
Figure 3: Effect of quercetin on Sirtuin isoforms and structure of Sirt2 in complex with 
quercetin. (A) Quercetin effects on the deacylation activities of Sirtuin isoforms. (B) Overall 
structure of human Sirt2 (cartoon presentation), ADP-ribose (yellow sticks), and quercetin 
(green sticks); His187 at the active site is represented in sticks. (C) Close view of the 
Sirt2/quercetin complex, interacting residues are labeled and quercetin (green sticks) is 
covered with 2Fo-Fc density contoured at 1σ. (D) Schematic view of the Sirt2/quercetin 
interactions. (E) Overlay of the Sirt2/quercetin complex (cyan cartoon, green ligand) with a 
Sirt2/myristoyl-peptide complex (gold cartoon, wheat peptide; PDB code 4Y6O). Dotted 
circle: steric clash between substrate and quercetin. (F) Effects of quercetin on Sirt2 
deacetylase activity at various substrate concentrations. (G) Overlay of the Sirt2/quercetin 
complex (cyan) with Sirt1 (red; PDB code 5BTR), Sirt3 (yellow; PDB code 4HD8) and Sirt5 
(magenta; PDB code 4HDA). (H) Overlay of the Sirt2/quercetin complex (cyan/green) with 




Figure 4: Isoquercetin activates Sirt6 with improved isoform specificity. (A) Dose-
dependent effect of isoquercetin on Sirt6 deacetylation activity. (B) Effect of isoquercetin on 
the deacylation activities of Sirtuin isoforms. (C) Close view of the Sirt6/isoquercetin 
complex. Interacting residues are labeled and isoquercetin (wheat) is covered with 2Fo-Fc 
density contoured at 1σ. (D) Schematic view of the Sirt6/isoquercetin interactions. (E) 
Overlay of the Sirt6 complexes with quercetin (cyan) and isoquercetin (wheat), respectively 
(protein of isoquercetin complex omitted for clarity). (F) Overlay of Sirt2 (grey cartoon) with 
the Sirt6 complexes with quercetin (cyan) and isoquercetin (wheat), respectively (protein 










Supplementary Figure 1: (A) Dose-dependent effects of quercetin on the fluorescence signal 
in control reactions for the FdL assay. (B) Quercetin titration yields concentration dependent 
inhibitory effects in coupled enzymatic assays in Sirt6samples (○) but also in control reactions 
without Sirtuin (▲ ). (C) Overlay of the Sirt6/quercetin complex (gray cartoon, cyan ligand) 
with a Sirt6/myristoyl-peptide complex (orange cartoon and peptide, PDB code 3ZG6).  
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Supplementary Figure 2: (A) Overlay of the Sirt6/ADP-ribose/CG complex (gray cartoon, 
cyan ligand) with a Sirt3/acetyl-ACS peptide/carba-NAD+ complex (PDB ID 4FVT; protein 
hidden, peptide displayed in orange and carba-NAD+ as cyan sticks). (B) Close view of the 
Sirt6 acyl group binding channel of the Sirt6/ADP-ribos/myristoyl peptide complex structure. 
Myristoyl group (orange), ADP-ribose (green) and residues that form hydrophobic 
interactions with the myristoylated lysine are represented as sticks. (C) Overall structure of 
human Sirt2/ADP-ribose/quercetin complex (cartoon presentation of two symmetry-related 
monomers in different colors). ADP-ribose (yellow) and quercetin (cyan) are shown as sticks.  
(D) Overlay of the Sirt6/ADP-ribose/quercetin complex (gray protein, quercetin shown as 
cyan stick) with Sirt1 (yellow; PDB code 4IF6), Sirt2 (green; PDB code3ZGV), Sirt3 (pink; 
32 
PDB code 4FVT) and Sirt5 (red; PDB code 4G1C). Dotted circle: Cofactor-binding loop and 
neighboring helix bundle. 
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